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 ABSTRACT 
Introduction: Lung cancer is a high pain cancer that can require the attention of clinical 
specialists.  Already vulnerable populations, like those that inhabit rural areas, when 
dealing with chronic diseases, like lung cancer, need and deserve adequate medical 
attention. However, rural communities often lack clinical specialists and are left without 
the needed care.  It is necessary to investigate the current availability of treatment options 
(medications) available to cancer patients in rural communities. Gaining this knowledge 
can result in economic savings and improvement of the quality of life for rural 
populations. 
Methods: Medicaid data from 1996-2010 was used to examine geographical disparities 
(urban and rural) in the state of South Carolina.  Medicaid recipients identified as distant 
stage lung cancer patients were linked with data from the South Carolina Cancer 
Registry. All patients included in the sample were either prescribed an opioid or analgesic 
and were continuously enrolled in Medicaid for at least 9 months prior to diagnosis 
(N=1,334).  Using the weighted data, logistic regression and Cox Proportional Hazard 
analyses were performed to assess the likelihood of disparate health care treatment and 
the survival rate of patients in the sample. 
Results: Findings of the conducted logistic regression were not statistically significant. 
This indicates that none of the variables analyzed in the patient factor or structure and 
process of care components were directly associated with patient receipt of medications. 
For the Cox Proportional Hazard model, gender was the only statistically significant 
  vi 
 variable that emerged from the model. Males (OR=1.31, CI: 1.03-1.65) were more likely 
than females to experience cancer-related death than females. Considering patient and 
provider geography, there was a greater presence of cancer specialists in the urban areas 
of South Carolina.  The deficit of clinical resources referred to a lack of cancer specialists 
to treat and prescribe medications appropriately as well as pharmacies to fill 
prescriptions.   Each having the potential to impact the manner of health care treatment as 
well as influence the longevity of a patient’s life.   
Conclusion: The disparities in access to care in the urban and rural regions of South 
Carolina indicate the need for policy that improves the availability of specialty clinicians 
in rural areas as well as rural residents’ access to pain medications.  With proper 
regulatory stipulations in place, the concerns of substance diversion and dependence 
would decrease. The development of local and federal government policy is necessary to 
increase the degree of pain control among these populations. 
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 CHAPTER 1 
 INTRODUCTION 
Lung cancer is the most frequently diagnosed cancer and pain is the most 
commonly experienced symptom (Simmons, MacLeod, Laird, 2014). Pain signifies a 
prominent medical, social and economic issue. It is estimated that the prevalence of 
chronic pain ranges from 8% to more than 60%, amongst the general population (Phillips, 
2003). While medications available to relieve pain are innumerable, pain is the primary 
cause for individuals seeking medical attention (Berry, Dahl, 2000).  Not only does this 
increase utilization of the health care system, it drastically impacts health care cost.  The 
needed clinical attention of those affected by pain increases the significance of improving 
the manner in which pain is assessed and treated, specifically in cancer patients.  
 Pain management is considered to be adequate if there is resemblance between 
the patient’s reported degree of pain and the appropriateness of analgesic therapy 
(Denadrea, Montari, Moja & Apolone, 2008). As a result of inadequate pain 
management, multiple studies document the frequency of uncontrolled pain ranging from 
74% to 95% in the ill and declared hospice patients (Berry, Dahl, 2000).  Pain is a chief 
concern for persons diagnosed with cancer (Herr, et al, 2012).  Approximately 75% of 
cancer patients experience pain during the course of the disease, approximately 40% 
report inadequate analgesia, and 50%-80% of cancer patients report inadequate pain 
management that affects activities of daily living (ADLs) (Randall-David, Wright, 
Porterfield, Lesser, 2003; & Berry, Dahl, 2000). The impact of pain on the functional 
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 status of patients is significant, especially as many diseases, specifically cancer, are 
managed on an outpatient basis, where individuals are cared for in the home by remote 
clinical and family caregivers (Ferrell, Ferrell, Ahn, & Tran K, 1994).  
The control and alleviation of pain has become a main concern in oncology (Paice 
& Ferrell, 2011). Pain has been identified as a symptom of cancer disease as well as a 
side effect cancer treatment. It is estimated that 30-45% of cancer patients in the early to 
intermediate periods suffer with moderate to severe pain; 75% of cancer patients in the 
advanced stages suffer with moderate to severe pain; and 25-30% of cancer patients in 
the advanced phase experience severe pain (Pargeon & Hailey, 1999). However, experts 
state that approximately 90% of cancer patients could be relieved of pain through the use 
of appropriate pharmacological treatment (Pargeon & Hailey, 1999; Portenoy & Lesage, 
1999). The successful management of cancer pain is necessary for the improvement of 
cancer survivorship, quality of life, and end-of-life care (Paice & Ferrell, 2011).  Reasons 
for the ineffective relief of cancer pain range from improper utilization of opioids, 
institutional, geographical, and societal barriers (Deandrea, Montanari, Moja, & Apolone, 
2008).  Obstacles to cancer pain management were specifically identified in 1994 by the 
Agency for Health Care Policy and Research; this was the first nationwide clinical 
publication of its kind (Agency for Health Care Policy and Research, 1994).  Additional 
identified barriers include inadequate pain assessment as a result of unqualified 
clinicians, the lack of patient-clinician communication, patient fears, and the absence of 
and access to pain medication- especially within minority neighborhoods and regions 
(Paice & Ferrell, 2011).
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 Pain assessments should be viewed as a basic component in routine cancer                                                                                                                                                                                                                                  
care. (Portenoy, 2011). A comprehensive assessment of pain in cancer patients to identify 
the relationship between the pain and the cancer is elemental in the treatment of cancer 
pain.  The evaluation should be thorough enough to identify the need for additional 
assessments and a feasible strategy of care. (Portenoy, 2011). This assessment can offer 
clarity regarding the impact of pain on the pathogenesis of the disease and the patient’s 
quality of life (Portenoy & Lesage, 1999).  A complete and sufficient evaluation 
investigates the multi-dimensionality of the pain and the cancer (Portenoy & Lesage, 
1999).  However, because of the varying personal measurements of pain, the patient’s 
report of pain is chief in the assessment (Portenoy & Lesage, 1999; Paice & Ferrell, 
2011).  Candid communication between the patient and clinician in combination with 
diagnostic results and laboratory and imaging reviews, enables an initial determination of 
the degree of pain and stage of the disease (Portenoy & Lesage, 1999). Diagnostic 
inferences are made from this relationship. The reluctance of cancer patients to accurately 
report pain to physicians is key in the inadequate treatment of cancer-related pain (Paice 
& Ferrell, 2011).  Oncology patients are hesitant to report pain due to fear that pain 
equates to disease progression, the misunderstood perceptions about opioid usage, or the 
possibility of physicians being distracted from the ultimate goal—disease treatment and 
increased longevity (Herr, et al, 2012; Carlson, Morrison, Holford, & Bradley, 2007; & 
Ferrell, Ferrell, Ahn, 1994). 
In the treatment process of cancer, it is recommended that pain is assessed 
frequently once treatment has begun (Pargeon, Hailey, 1999). This could present a 
challenge for cancer patients that reside in areas where access and quality issues are 
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 constants.  Cancer patients who live in rural areas have few options other than to seek 
medical care from “generalists”, also of whom there are shortages to treat populations in 
these areas, who are untrained in pain assessment (Kelley, 2007). Insufficient pain 
management embodies a public health issue that plagues minority, rural and underserved 
populations who often suffer due to the healthcare disparities that plague this group— 
inadequate access to prescription opioid analgesia, usually prescribed for cancer patients 
to alleviate pain associated with the disease, the deficit of clinical specialists, and 
regulatory safeguards (Tollefson et al., 2011; Webster et al, 2007; Weisse, Sorum, 
Sanders, Syat, 2001).  
Rural communities present unique challenges to cancer pain management (Baltic, 
2002). Barriers to pain management in rural communities include attitudinal biases, fear 
and misconceptions of patients and families, and regulatory concerns (Baltic, 2002). In 
addition, the availability of opioids, used for pain management in cancer, are perceived to 
be in low demand and stocking opioids carries a high risk of safety concerns (Francouer, 
2011; Baltic, 2002). The demographics, lower socioeconomic status and educational 
attainment and the higher number of uninsured population, of these communities impede 
the availability and access to such medications (Baltic, 2002). In addition it is difficult for 
rural communities to attract and retain specialists in pain or cancer care (Kelley, 2007). 
The limited and aged, nationally and state-specific, literature referencing cancer pain 
management in rural communities highlights the need for this focused and specific 
research agenda.
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 This study aims to examine medication treatment options for distant stage lung 
cancer patients in rural South Carolina and the impact of patient geography and ethnicity. 
The primary aim of this study is to examine the association of the availability of 
medications that treat cancer pain, a primary side effect of distant stage lung 
cancer, with patient factors and geography. The combined influence of these variables 
on the rate of patient survival was the primary outcome of interest. To date, no published 
studies were discovered that examined cancer pain management and its possible 
association to survival in a state-based insurance database in the state of South Carolina 
or other like geographical regions within the target population.  This investigation 
explores the availability of pain medication based on race and ethnicity and geography as 
well as the impact of the receipt of medication on patient longevity and survivorship. 
Rural residents face increased difficulty accessing health services and providers 
(Tollefson, et al, 2011). This lack of access is not only evident in the scope of access to 
health services and providers, but also in the lack of availability of prescription drugs to 
aid in pain management (Francoeur, 2011). Unfortunately, rural residents with chronic 
pain are often placed in an even more vulnerable state, as they are sometimes forced to 
forego the needed health services and adequate relief of pain. This is due to the limited 
availability of medications, trained clinicians, and decreased access to health care 
facilities.  
It is because of rural community’s inability to attract and retain health 
professionals and healthcare facilities that pain management care is usually provided by 
health care generalists, not pain management specialists (Kelley, 2007). In addition, 
pharmacists and pharmacies in rural, areas may not stock opioids, commonly used for 
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 pain, because of safety and cost-effectiveness concerns (Francoeur). Rural areas often 
endure the brunt of economic strain without needed health care services due to pressure 
by health insurers to limit coverage on less cost-effective options, combined with health 
institutions and patients’ out-of-pocket restrictions. (Francoeur; Morrsion et al, 2011)  
Health providers in rural areas also find it difficult to obtain medications because of 
higher costs and safe delivery concerns (Francoeur).  
Each of these factors significantly affects the management of pain in patients in 
rural areas. Effective pain relief is significantly dependent upon a comprehensive 
assessment that highlights physical, psychological, social, and spiritual aspects for 
intervention (Paice, Ferrell, 2011).  However, the limited availability of literature about 
the role the availability of prescribed pharmaceuticals plays in cancer pain management 
in rural areas only encourages the need to further examine (Kelley, 2007; Robinson, 
2009).  Effective pain management has a significant impact on the quality of life, health, 
and socioeconomic circumstances (Green, et al, 2003). 
The Patient Protection Affordable Care Act highlights pain management with 
provisions extracted from the National Pain Care Policy Act. Proposed efforts include 
training for clinicians to improve care for pain, confronting barriers to care in 
underserved groups, and programs that specifically assess the impact of provider’s 
knowledge on the practice of pain care (Affordable Care Act, 2010).  
In the 2013 Progress Report Card, The American Cancer Society assigned the 
state of South Carolina a grade of “B+” for implementing pain management policies 
throughout the state (Pain & Policy Studies Group, 2013). This is an improvement over 
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 the 2006 grade of “B”, but there has been no improvement of the grade “B+” since 2007.  
It was hypothesized that distant stage lung cancer patients who lived in rural areas were 
at a greater risk for experiencing cancer-associated pain and would not receive adequate 
treatment for this pain (needed analgesic medications).  In turn, it was also hypothesized 
that this inadequate treatment of patient’s healthcare needs would decrease patient’s 
survival rate. 
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 CHAPTER 2 
BACKGROUND AND SIGNIFICANCE 
RATES OF CANCER IN SOUTH CAROLINA 
The American Cancer Society predicts an estimated incidence of 25,550 cases of cancer 
in South Carolina (2015).  Of this, 4, 040 will be lung cancer cases. Advancements in the 
treatment of cancer have revealed an array of medications and drug combinations that 
focus on disease-specific treatments and symptomology, treating only a portion of the 
problem.  These methodologies do not address the need for clinicians and healthcare 
systems to be prepared to provide the necessary care for the whole scope of treatment 
(Payne, 2000). 
According to the South Carolina Cancer Registry, the 2009 incidence rate of cancer for 
the state of South Carolina was 442.7 per 100,000 (CDC, 2009) (Table 2.1).  The cancer 
mortality rate was 178.6 per 100,000 (Table 2.2).  Of the 4,723,723 people that live in 
South Carolina, 1,089,723 live in areas defined as rural (Rural Assistance Center, 2013).  
All of South Carolina’s 46 counties are designated as whole or partial Health Professional 
Shortage Areas (HPSAs), highlighting the problem for rural South Carolina (South 
Carolina Office or Rural Health, 2013).  Of the 46 counties, 35 are designated as wholly 
or partially rural areas according to the Economic Research Service Rural-Urban 
Commuting Areas (RUCA) (“USDA”, 2010).  The RUCA system uses census tracts to 
categorize applying the same concepts that the Office of Management and Budget uses; 
in addition, measures of population density, level of urbanization, and average daily
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 commute are used to make the distinction between micropolitan and metropolitan areas, 
adjacent tracts that are socially and economically incorporated, as well as rural tracts 
(“USDA”, 2003). 
CANCER CARE IN RURAL REGIONS 
 
During the 2010 United States Census, approximately 19% of the United States 
population lived in an area designated as rural (US Census Bureau, 2010).  In regions 
with access issues, proximity to specialized care can pose problems and influence both 
access and utilization. Specifically for cancer patients, extended travel times have been 
associated with advanced stages of the disease (Onega, et al., 2008).  This can be 
attributed to the greater likelihood of lower socioeconomic status and decreased chances 
of survival among residents of rural areas.  Patients with limited access presenting with 
advanced stages of the disease could also be associated with the greater likelihood of 
receipt of poorer treatment, generating poorer outcomes within regions designated as 
rural (Jong, Vale, & Armstrong, 2005). 
In the advocacy for holistic, interdisciplinary cancer care, additional factors 
must be considered for rural populations.  There is the constant question of who from the 
needed clinical disciplines is available to assist and meet the needs of cancer patients 
within rural areas? Generalists, alone, are primarily responsible for the delivery of 
clinical and psychological care for these patients; yet, generalists may not be adequately 
equipped for these responsibilities (Watanabe et al., 2013; Kelley, 2007).  Such issues 
linger and manifest as medically unmet needs in rural regions. 
Addressing the inequalities in cancer care and outcomes faced by rural residents, 
requires improvement in access and delivery of primary healthcare, access to clinical
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 specialty services, and a coordinated continuum of clinical care.  A major concern 
is the deficit of needed evidence to effectively guide and identify the placement of 
additional resources in  the rural areas (Jong, Vale, & Armstrong, 2005).  Current policies 
and legislation are fortified by the simple belief that patients should have access to 
quality health services that are as near to their homes as geographically possible.  
However, geographic variation is often unpredictable in rural areas, which impacts time 
and period of diagnosis, stage of disease, and outcome of the diagnosis and disease (Jong, 
Vale, & Armstrong, 2005).  Efforts to increase the care being provided by specialists in 
rural areas include videoconferencing and telemedicine. Each has become integral 
components in the rural continuum of cancer care.  A 2013 Canadian study indicated that 
these forms of care have demonstrated themselves to be both time- and cost-effective 
with both the patient and the provider reporting a high-degree of satisfaction (Watanabe). 
 Nevertheless, the establishment and implementation of an efficient and effective  
 
health care system that practices coordinated care with fidelity would require progressive  
 
information systems, actual collaboration between and within multidisciplinary teams,  
 
services, and regulatory bodies.  Remoteness and scarcity of service providers may make  
 
this task increasingly difficult for rural areas (Jong, Vale, & Armstrong, 2005). Patients 
with diminished access to care are more likely to postpone treatment for pain (Francoeur, 
2011). This could especially relate to persons who find themselves isolated from medical 
providers. For rural areas isolation is an evident barrier, and as a result many rural 
residents are often forced to endure the pain and suffering commonly associated with 
cancer. 
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 INTERSECTION OF RACE AND GEOGRAPHY IN CANCER CARE AND CANCER PAIN 
MANAGEMENT 
 
 Pain is a measurable concept that can have varying perceptions based upon 
personal experiences and cultural expectations (Bonham, 2001). Cleeland et al’s 1994  
study of cancer treatment within multiple cancer centers found that cancer patients 
receiving outpatient therapy at clinics that had a greater service population of “ethnic and 
racial minority patients” were three times more likely to be under medicated with 
analgesics than were patients in other settings (1994).  Patients indicating inadequate 
analgesic treatment were also more likely to be receiving their treatment in a community 
clinical oncology program, where the primary goal is to bring clinical trials to patients in 
their local communities. In addition, Cleeland discovered that regardless of the clinical 
setting, minority patients were still more likely to receive inadequate analgesia (1994).  
 Cleeland et al’s 1997 follow-up study examined the degree of cancer-related pain 
experienced and the appropriateness of medication prescribed for pain relief. The follow-
up study also found that patients who received treatment in a clinical setting that 
primarily services minority patients, either African American or Hispanic, were more 
likely to receive inadequate pain medication than those who received treatment in a 
community clinic setting that did not primarily see minority patients. In addition, the 
1997 study found that minority patients were more likely to have the degree of their pain, 
as they reported to the clinician, underestimated by the physician (Bonham, 2001; 
Cleeland, 1997).  Cleeland and colleagues discuss that potential causes for the stated 
disparities in pain assessment and determination may be the patient being intimidated by 
treatment and treatment alternatives; less economic and regulatory resources to provide 
minority patients with the needed pain medications; patients not being insistent about 
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 their health care; lack of clinical expertise in assessment of patient conditions; and 
cultural and language barriers (Bonham, 2001; Cleeland, 1997; Cleeland, 1994).  
Cleeland’s studies emphasize the significance of selecting the proper type of healthcare 
facility (Bonham, 2001); however, for rural patients who do not have the option to choose 
the type of health care facility suboptimal health care may be the only option. 
 
CANCER PAIN MANAGEMENT: A GROWING PRIORITY IN ONCOLOGY CARE 
The pathophysiology of cancer incorporates multiple diseases of multiple variations.  
Symptom distress significantly influences the manner and approach of care for cancer 
patients (Portenoy, 2011).  Chronic pain is one of the most significant symptoms in 
cancer.  Pain in cancer patients and cancer survivors receive subpar descriptions, and 
currently there are no standard procedures in place regarding the methodology of 
treatment and best practices in this population where the degree of disease and pain 
greatly varies (Portenoy, 2011).  In advanced stages of the disease severe pain affects 
approximately 70-80% of patients (Pargeon & Hailey, 1999; Caraceni et al., 2012).  As 
the focus placed on the degree of understanding and skill involved in the evaluation of 
and tending to cancer pain progresses to the notion of patients being entitled to effective 
pain management; the breakdown to provide efficient pain management demonstrates the 
inadequate delivery of medical care and the failure of the healthcare system in its 
responsibility to meet the needs of cancer patients (Ashburn, 2008). 
Pain can be a direct result of the disease or the therapy associated with treatment 
of the disease.  Pain has also been found to be the most anticipated and feared symptom 
of cancer (Nersesyan & Slavin, 2008). Conventional methods of pain control do not meet 
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 the needs of a portion of the cancer patient population; however, an emerging continuum 
to include innovative, efficient practices is being executed as a result of the recognized 
need for alternative methods of  pain control and the consistently increasing incidence of 
cancer (Gulati, Joshi, Baqai, 2012).   
 
PREVALENCE OF CANCER PAIN AND THE UNDERTREATMENT OF CANCER PAIN 
The American Cancer Society reports expected 1,665,540 new cancer cases  
in 2014 (American Cancer Society, 2013; Siegel, Ma, & Jemal, 2014).  Among these 
cancer patients, their pain experiences will vary depending upon the stage of the disease 
and the type of cancer.  For newly diagnosed patients the prevalence of pain is 
approximately 25%; 33% for patients undergoing active therapy; and the prevalence of 
pain exceeds 75% for cancer patients in the advanced stages of the disease (Paice & 
Ferrell, 2011). Chronic pain, referred to interchangeably with pain in this context, 
experienced by those diagnosed with cancer who have concluded treatment is 
approximated to be 33%. (Paice & Ferrell, 2011). 
Because the occurrence and incidence of cancer is increasing, cancer pain 
should be expected and attended to as soon as possible instead of at later stages (Paice & 
Ferrell, 2011).  Utilizing the pain management index, Cleeland’s 1994 examination 
revealed that 42% of metastatic cancer patients were given insufficient anesthetics at an 
inadequate strength level (Cleeland, Gonin, Hatfield, Edmonson, Blum, 1994; de Wit, 
1999). Additional studies that used a pain management index to assess the level of pain 
demonstrated that 27% to 74% of cancer patients received inferior cancer pain treatment. 
(de Wit; Bekkering et al., 201
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 Reasons for the under treatment of cancer pain vary. The under treatment of 
cancer pain can be related to inaccurate assessments of pain by clinicians,  the manner in 
which the pain is reported by the patients and the misuse of opioids as a result of 
barriers—family, patient, provider, social, and organizational (Deandrea, Montanari, 
Moja, & Apolone, 2008; Kroenke, Theobald, Wu, & Krebs, 2012). Additional elements 
that complicate the management of cancer pain are patients who experience inconsistent 
pain, neuropathic pain, those who suffer from substance abuse issues, and those with 
limited intellectual or communication abilities (Thapa, Rastogi, & Ahuja, 2011). 
 Barriers highlighted in a 1995 report are barriers still encountered by both patients 
and physicians today (Thapa, Rastogi, & Ahuja, 2011).  Attempts to emphasize the need 
for standardized approaches to cancer pain treatment highlight the necessity for the 
further evaluation of the efficacy of pain assessment tools and resources to establish 
benchmark pain evaluation techniques (de Wit et al., 1999). 
PAIN MEDICATIONS AND CANCER SURVIVORSHIP 
 Opioids have been considered the “gold-standard” for the relief of chronic cancer 
pain for over 200 years  (The Unviersity of Chicago-Medicine, 2012). Required opioid 
doses for pain alleviation does vary with circumstance, cannot be predicted, and is 
impacted by many influences (Brescia, Portenoy, Ryan, Krasnoff, & Gray, 1992). A 1992 
study conducted by Brescia et al at Calvary Hospital inidcated that a lack of opioid dose 
escalation in patients with advanced cancer could be related to the immobility of this 
specific group of patients—also an indicator of quality of life. However, it is equally 
important to note that cancer patients who do use opioids as instructed will have 
14 
 increased survival times and those who do not remain compliant could have decreased 
survival times (Wade, 2013).  
Opioid Dosage and Impact of Opioid Usage for Advanced Cancer Suvivorship 
Studies  
A study conducted in a palliative care setting examined the common concern of 
clinicians that the dosage of opioids used resulted in a quicker demise of the patients 
(Alsirafy, et al., 2013). Patients were categorized according to dosage: low dose (<120 
mg in a 24-hour period), intermediate dose ( 120-<300 mg in a 24-hour period), and high 
dose (≥300 mg in a 24-hour period). The investigation examined the relationship between 
survival and the dosage of opioids advanced cancer patients received. Patients were 
receiving a mean dosage of 167 mg per day. The final result demonstrated that opioid 
dosage had no influence on survival in patients with advanced cancer, including lung 
cancer, in this setting (Alsirafy, et al., 2013). Patient insurance type and geography were 
not reported.  
 Published in 2001, Morita, examined the effects of opioid dosage in hospice 
inpatients. Over 80% of patients were prescribed opioids with a median dose of 80 
milligrams per 48 hours. Dosages were categorized as low (< 240 mg in a 48-hour 
period), intermediate (240-599 mg in a 48-hour period), and high (≥ 600 in a 48-hour 
period). The final result demonstrated that opioid dosage had no influence on survival in 
patients with advanced cancer, including lung, in this setting (Morita, Tsunoda, Inoue, & 
Chihara, 2001). Patient insurance type, race/ethnicity, and geography were not reported.  
 The 1997 study lead by Bercovitch, Waller and Ansdunsky examined the medical 
records of 651 inpatients hospitals at their medical center. The mean daily morphine 
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 given to patients was categorized by age and ranged from <60 mg to >599 mg. The final 
result demonstrated that morphine dosage had no influence on survival in patients with 
advanced cancer, including lung, in this setting (Bercovitch, Waller, Adunsky, 1999). 
Patient insurance type , race/ethnicity, and geography were not reported.  
 Thorn and Sykes (2000)  examined 238 who dies in a palliative care unit. Within 
the last week of life in the 24-hour period, daily dosage of opiods were recorded. During 
the last week of life, the average daily dose increased rom 42 milligrams to 55.5 
milligrams. The final result demonstrated that morphine dosage had no influence on 
survival in patients with advanced cancer in this setting (Thorn & Sykes, 2000). Patient 
insurance type , race/ethnicity, and geography were not reported.  
  Azoulay et al. reviewed hospice admissions from June through November 2006 
(2008). Data regarding demographics, primary tumor site, presence of metastases on 
admission, opioid dose upon entry to the hospice and on the last day of life, and length of 
survival in the hospice were documented (Azoulay et al., 2008). From the 94 patients  
who entered hospice during this period, 63% received opioids and 56% required an 
increase in opioid dosage. There was a correlation between prolonged life and increased 
opioid dosage. Patient insurance type , race/ethnicity, and geography were not reported.  
From February 2000 to December 2000, Good and colleagues (2005) conducted 
a review of medical records and medication charts for all deaths of patients admitted to 
hospice. The investigators examined survival in patients on opioids during the last 24 
hours of life.  There was no association found between opioids and decreased survival. 
However, inpatients that were administered a higher dosage, greater than or equal to 300 
milligrams per day, as opposed to the lower (less than or equal to 120 milligrams) or mid-
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 range dosages 120 to 299 milligrams, experienced an increased survival period (Good, 
Ravenscroft, Cavenagh, 2005). One possible explanation the authors provide for this 
increased survival time was the potential relationship with better pain control as a result 
of opioid usage. Patient insurance type , race/ethnicity, and geography were not reported.  
 
 Two studies considered the relationship between opioid dosage and survival in the 
home health care setting. The 2004 published lead by Bercovitch and  Ansdunsky 
examined the medical records of 661 patients enrolled in home healthcare hospice. In the 
study, 66% of patients were receiving morphine for pain relief. Dosages ranged from 5 
milligrams to over 600 milligrams per day. The use of the increased dosage did not have 
an adverse impact on patient life expectancy (Bercovitch & Andunsky, 2004). The final 
result demonstrated that morphine dosage had no influence on survival in patients with 
advanced cancer, including lung, in this setting (Bercovitch & Adunsky, 2004). Patient 
insurance type , race/ethnicity, and geography were not reported.  
 The second home health care study was conducted by Bengoechea et al. from 
2003 to 2007 (2010). This review of 223 oncology patients of the Hospital at Home unit 
found that the median survival time was longer for patients who received higher doses 
than lower doses of opioids. Regular doses were less than 120 milligrams and higher 
doses were defined as more than 120 milligrams. However, after adjusting for 
demographic and clincial variables, the differences dissolved. Patient insurance type, 
race/ethnicity, and geography were not reported (Bengoechea, Gutierrez, Vrotsou, 
Onaindia, Lopez, 2010).  
Each of the previously delineated studies provides insight about the relationship 
between medication dosage and survival of cancer patients and the non-existent level of 
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 clarity that exists around this matter. However, the role of the physician remains key 
when examining the treatment of cancer patients.  
 
PHYSICIAN ATTITUDE AND RATIONALE INFLUENCING CANCER PAIN MANAGEMENT  
Generalists and oncologists have an overall insufficient breadth of knowledge of 
pain management and lack the skills to properly practice pain management therapy 
(Breivik et al., 2009; Gallagher, Hawley, & Yeomans, 2004; Okuyama, et al., 2004). 
Between 2007 and 2008, a 40-question questionnaire was distributed to 98 Finnish 
oncologists and a total of 2,055 generalists, specialists, and internists. The questionnaire 
revealed a significant difference between the pain management knowledge of oncologists 
and physicians (Silvoniemi, et al., 2012).  Over 60% of the oncologists assumed their 
current knowledge of the WHO analgesic ladder was correct; however, only 46% of 
oncologists could remember the number of steps and the order of opioid application for  
the analgesic ladder as well as the WHO’s suggestion of medication for  ingestion 
primarily by mouth.  In addition, 80% of oncologists replied pain therapy should only be 
provided as needed compared with 2% of physicians (Silvoniemi, et al., 2012). As 
expected of trained oncologists, the Finnish study showed that oncologists had a clearer 
understanding that increasing the quantities of opioids during the course of the disease 
does not increase the potential risk for efficacy of the medication (Silvoniemi, et al., 
2012).  
A 2009, 46-item questionnaire was disseminated nationally to 2,000 actively 
practicing oncologists, inclusive of palliative care and pain management specialists.  The 
survey contained numeric rating scales to evaluate physician attitudes and behavior 
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 regarding pain management and posed situational questions to examine the physician 
knowledge and attitudes towards prescribing opioids and opioid safety (Breuer, 
Fleishman, Cruciani, & Portenoy, 2011). Study results indicated that oncologists 
perceived the reports of pain provided  by patients to be an accurate report of pain and 
that oncologists offered effective pain management, yet they were “less conservative” in 
their prescribing of opioids when compared to general physicians and other specialists 
(Breuer, Fleishman, Cruciani, & Portenoy, 2011). Most importantly, the surveyed 
oncologists believed that the greatest obstacles to effective pain management were: the 
assessment of pain, patients not wanting to take opioids, and patient hesitation to report 
pain (Breuer, Fleishman, Cruciani, & Portenoy, 2011).  The oncologist’s responses 
corresponded with the standard of clinical care when asked questions concerning 
common clinical practices.  Surveyed oncologists were more likely to contend that opioid 
therapy is the primary line of treatment for patients with active cancer and that routine 
administration of opioid therapy is more effective than administration when chronic pain 
is present (Breuer, Fleishman, Cruciani, & Portenoy, 2011).  
The results presented in this 2009 survey, mirrored those of a 1990 
questionnaire distributed by Von Roenn et al. (1993).  This is a clear indication of the 
lingering issues surrounding cancer pain management.  The ratings of pain management 
have not evolved as one would assume, especially in an era of progressive technology 
and medication. Oncologists perceive that this lack of progress remains related to the 
previously mentioned barriers: inferior pain assessment, patients not reporting pain, and 
patients not wanting to take prescribed opioids (Breuer, Fleishman, Cruciani, & Portenoy, 
2011). These barriers continue to reinforce the need for cancer pain therapy that is 
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 tailored for each individual patient and addresses both the challenges and benefits when 
the ultimate goals, improved quality of life and increased life expectancy, are considered.   
 
UTILIZATION OF OPIOID ANALGESICS FOR PAIN CONTROL 
 
The WHO estimates that approximately 80% of cancer patients do not have proper access 
to opioids (Thapa, Rastogi, & Ahuja, 2011).  The WHO established a platform to 
improve cancer pain therapy in 1982.  In 1986 the recommendations were printed, with 
an update being made in 1996.  These guidelines are founded on the principle of routine 
administration of pain medication following a three-step ladder, for each individual 
patient.  (Wahlberg, Vuorinen, Clemens, & Salminen, 2012).  The ladder serves as a 
guide for the administration of opioid therapy relevant to the level of pain.  
Opioid-centered therapy is the primary line of therapy for cancer pain.  It should 
be the goal of practitioners who prescribe opioids to offer cancer patients therapy that 
optimizes the potential for positive outcomes and decreases the potential for possible side 
effects and possible substance abuse.  Successful opioid treatment depends greatly on the 
drug selected for therapy, the selected dosage, and the manner in which the side effects of 
the drugs are treated (Portenoy, 2011).  In 1996, the WHO developed a visual aid to 
complement the already developed analgesic ladder as a depiction of the recommended 
guidelines to be adopted by clinicians and oncologists to aid in the relief of cancer pain 
(Figure 2.1). The analgesic ladder is utilized internationally but has not been updated to 
maintain compatibility with current clinical practices, recommendations and therapies 
(Caraceni, 2012).   
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 Optimal strategies with optimal benefits for pain relief entail analgesia with oral 
opioids, adjuvant analgesics, and progressive pain management practices. Nevertheless, 
the potential risks of these therapy regimens must be measured (Rana, et al., 2011). 
Improvements in the availability of oral opioid and interventional pain management 
techniques can serve as an aid in the breakdown of the barriers of treating cancer pain, 
while enhancing patient quality of life. Such improvements in cancer pain therapy, the 
increase in the availability and accessibility to opioids, nerve blocks, other non-invasive 
techniques relevant to palliative care which considers the whole being and those they 
surround themselves with, can result in adequate pain relief for most patients (Portenoy, 
2011).  
Figure 2.1 The World Health Organization’s Analgesic Ladder (1996) 
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 Adopting a consistent routine of opioid use in patients should effectively offer 
relief from chronic cancer pain with manageable side effects, overall improving patient 
quality of life (Portenoy, 2011).  Opioids are agonists that become active by binding to 
opioid receptors which are found in the membrane of neurons located in the pain related 
areas of the brain. These receptors are called mu, kappa and delta receptors.  The most 
essential is the mu-receptor (Schafer, 2010).  The majority of all prescribed opioids 
stimulate as a result of activation of the mu-receptor and are most commonly selected for 
cancer pain (Portenoy, 2011; Schafer, 2010).  While other options do exist, unadulterated 
mu-agonists, buprenorphine, tramadol, tapentadol, provide more dosing options 
(Portenoy, 2011; Schafer, 2010).   
Opioids are categorized according to how they bind to receptors in the body: full-
agonists (successful in increasing dosages with no plateau), partial agonists (plateau and 
are less effective than full agonists), or mixed agonists/antagonists (inhibit specific 
receptor activity while activating other opioid receptors) ( (National Institutes of Health, 
National Cancer Institute, 2014). In cancer pain management the most commonly 
prescribed opioid is morphine, primarily because of clinical familiarity and availability. 
Although many clinicians are comfortable with the chemical structure of morphine and 
how it reacts to cancer pain, it is still important to have a knowledge of the various 
opioids used to treat cancer pain.  
Opioids commonly prescribed to cancer patients are listed with a brief description 
of drug activity. Each of these opioids have been assigned to a step within the WHO 
ladder based on moderate or severe pain intensity. 
22 
 
  
Buprenorphine has been categorized as a mixed agonist/antagonist.  This drug attaches to 
the mu- and k-opioid receptor with a delayed onset, postponed optimal effect (3 hours) 
and is long-lasting (8-10 hours). 
 
Tramadol is a weak opioid assigned to step 2 of the WHO analgesic ladder. Tramadol 
attaches to norepinephrine and serotonin inhibitors, raising the levels of both 
norepinephrine and serotonin resulting in pain inhibition. 
 
Hydromorphone is a mu-opioid agonist assigned to step 3 of the WHO analgesic ladder. 
Hydromorphone has an average of four and a half times the pain reducing strength of 
morphine.  This drug can be administered orally and parenterally. 
Morphine is a strong mu-opioid agonist that is grouped into step 3 of the WHO analgesic 
ladder. Morphine is primarily used as a reference drug for all other opioids and can be 
administered via all routes. 
 
Oxycodone is a powerful mu-opioid that is only administered orally. This agonist belongs 
to step 3 of the WHO analgesic ladder and is 8 times more potent than morphine. 
 
Meperidine is a weak opioid mu-receptor that is grouped with step 2 of the WHO 
analgesic ladder. Meperidine has 0.13 the analgesic strength of morphine 
 
Methadone has a moderately long half-life and is cost-efficient when compared to other 
opioids.  Its effectiveness in the treatment of pain and the inexpensive nature of the 
medication has encouraged the increase in the use of methadone (Portenoy, 2011).  In 
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 addition, methadone is a drug that curves the appetite decreasing the possibility of 
substance abuse (Sandoval, 2005). 
 
Fentanyl is a strong opioid mu-agonist that has been categorized into step 3 of the WHO 
analgesic ladder. Fentanyl possesses 80-100 times the analgesic strength of morphine. 
Fentanyl has a fast onset but does not have a long-lasting effect. 
Sufentanil is an extremely aggressive mu-opioid agonist with 800-1000 times the 
analgesic strength of morphine.  When compared to fentanyl, sufentanil has a decreased 
risk of accumulation (Schafer, 2010). 
 
Opioids have been used for the past 200 years in various forms.  The 
administration of opioids to alleviate cancer pain remains common practice, especially 
according to the guidelines outlined by the WHO (Portenoy, 2011).  The pure mu-
agonists medications, like morphine and oxycodone, can be administered in miniscule 
doses. Smaller doses allow for the safe and successful management of moderate pain.  
The most important standard in the treatment of pain can be introduced with the routinely 
used pure agonist opioid drugs.  This characteristic of the opioid allows the clinician to 
isolate the drug that provides the optimal outcome for the patient (Portenoy, 2011; 
Schafer, 2010; Sandoval, 2005). 
South Carolina Opioid Prescribing Guidelines 
 
 South Carolina requires that a physician and a patient have a valid relationship 
before a physician can prescribe a controlled substance to the patient. Valid encompasses 
the physician having adequate knowledge of the patient’s medical history and the need 
and ability to confidently determine the potential risks and benefits that could befall the 
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 patient while taking this medication (Bolen, 2008).  In addition, South Carolina has a 
prescription monitoring plan that records the prescription fill and refill habits of patients 
prescribed these substances. 
Access levels to opioid treatment vary due to government regulation for the 
purposes of prevention and reduction of substance dependence.  However, because of its 
effectiveness for cancer patients, this should serve as a motivation for the clinical 
community to adamantly campaign for the increased regulation of the drug with 
increased, secured measures for access for the legitimate purposes (Portenoy, 2011; Okie, 
2010; Baltic, 2002).  Such an attempt will ensure that there are adequate supplies for 
those that require medication from this drug class, yet the increased regulatory process 
may reduce the prevalence of drug misuse. 
 
HIGH-PAIN CANCER IN SOUTH CAROLINA:  LUNG CANCER 
Nationwide, South Carolina has the 14th highest incidence of cancer (Lung Cancer, 
2010).  In South Carolina lung cancer is the leading cause of death among cancer deaths 
and is the second most frequently diagnosed cancer (South Carolina Cancer Alliance, 
2011).  A national meta-analysis completed by the International Association for the Study 
of Pain determined that the occurrence of pain for those diagnosed with lung cancer was 
47%, affecting 27% of outpatients and 76% of palliative care patients (IASP, 2009). A 
diagnosis of pain was associated with cancer (73%) and cancer treatment (11%) (IASP, 
2009).  
 Considering gender, males are twice as likely to be diagnosed with lung cancer 
as well as to die of the disease in South Carolina.  While Non-Hispanic Whites have a 
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 15% higher diagnosis rate and a 10% higher death rate than other races and ethnicities 
(South Carolina Cancer Alliance, 2010).  Lung cancers was selected because of its high 
pain prevalence in the later stages of the disease and its incidence and prevalence in the 
state of South Carolina.   
 
BARRIERS TO PROVIDING ADEQUATE CANCER PAIN MANAGEMENT 
 The absence of a clear understanding and clinical knowledge of the complexity 
of cancer pain and the management of cancer pain among health care professionals, 
patients, and the public; lack of institutional commitment; lack of proper regulatory 
control; and limited access to and reimbursement for interdisciplinary care all present 
substantial obstacles to the successful control of pain (Gordon et al., 2005).  Within 
health care systems, obstacles preventing adequate management of pain are clear 
evidence of the priority assigned to pain management.  The absence of sustainable  
policies; pain education initiatives and disjointed, uncoordinated care are all indications 
of systematic barriers (Gunnarsdottir, Donovan, & Ward, 2003).   
An additional challenge that presents an obstacle for healthcare systems and 
 
individuals, and specifically relevant to the issue of pain management, is the fact that pain 
is the most significant clinical symptom in regards to prevalence and outcomes, and 
application of evidence-based methodologies for the management of pain is essential 
(Portenoy, 2011).  For some patients, cancer care has evolved into a complicated 
structure of disjointed medical care.  Each interaction with a medical provider has a 
suited objective that is heavily influenced by psychosocial and mental components 
(Portenoy, 2011; Verhoef, Vanderheyden, & Fonnebo, 2005).   
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 Communication is a necessary interaction between the patient, the patient’s 
family, and the medical providers.  If this is restricted for any reason it can impact the 
outcome of the patient’s health care and the delivery of health care (Portenoy, 2011).  
Cultural beliefs, language barriers, or an uncomfortable patient-provider relationship, can 
lead to ambiguity about the goals of care, misconceptions and misunderstandings about 
the care the patient is receiving and plans of future care; especially if the care is outside 
of a clinical environment (Portenoy, 2011; M. Chang, Y. Chang, Chiou, Tsou, & Lin, 
2002). 
 A less evident barrier is the nonexistence of randomized controlled trials to 
provide support for suggested evidence-based practices (Caraceni, 2012).  The majority 
of randomized controlled trials focusing on pain control have low subject enrollment, 
give little insight about pain characteristics and processes, and involve diverse 
interventions and conclusions with expectations of generalizability (Carr et al., 2004).   
Such instances force reliance on the specialists who provide care to cancer patients. 
However, this also presents a dilemma as much of the medical attention sought is 
provided by primary care practitioners (Caraceni, 2012; Tollefson et al., 2011). 
 Regulatory barriers are most relevant to opioids. These barriers that are 
increasingly difficult to control because it is sometimes challenging to differentiate 
between the need for pain relief and the need to satisfy an addiction (Gunnarsdottir, 
Donovan, & Ward, 2003). Restrictions enforced by national and regional laws can be 
strict and excessive, mainly because of the potential for abuse (Bosnjak, Maurer, Ryan, 
Leon, Maiye, 2011).  While the concern of becoming addicted to opioids may be 
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 “exaggerated” and dated, there is ample evidence about the societal and economic impact 
of substance abuse (Bosnjak et al.). 
 
SOCIAL AND ECONOMIC DISPARITIES IN THE PROVISION AND RECEIPT OF CANCER PAIN 
CONTROL 
In addition to race and ethnicity, socioeconomic status, and other social demographics 
like education, insurance status, and geographic location are interlinked in the description 
of disparities in pain management (McNeill, Reynolds, & Ney, 2007).  Patient 
characteristics can also be a likely predictor of who will not be provided adequate pain 
relief.  While not a sole determinant, patient’s race and ethnicity are critical factors of 
treatment received.  The locality of the treatment facility has also been found to be an 
important factor (Gunnarsdottir, Donovan, Ward, 2003).  An additional demographic 
determinant is the under treatment of pain according to gender.   
Mounting evidence supports that populations of a lower socioeconomic status 
are not only at greater risk of being diagnosed with cancer but also being diagnosed at a 
later stage with inferior outcomes (McNeill, Reynolds, Ney, 2007).  The poor are more 
likely to be the racial minority.  Poor individuals that reside in rural areas are also more 
likely to be either uninsured or underinsured than inhabitants of urban areas. This lack of 
coverage limits access to healthcare and needed medications (McNeill, Reynolds, & Ney, 
2007).  More specifically pain medication is prescribed to suit the needs of the particular 
patient and costs can be excessive.  Lacking the financial means to purchase the pain 
medication can result in poorer health outcomes (Freeman, 2004; McNeill, Reynolds, & 
Ney, 2007).  In South Carolina, the 2012 rural poverty rate was 22.5% compared to 
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 17.7% in the urban areas and the average per capita income rural regions was $30,304 —
$3,084 less than the urban comparison, (Rural Assistance Center, 2013). In addition, the 
poor are more likely to have less than appropriate or the complete absence of pain 
management plans in place.  They may also be less educated about the pain management 
process and what is defined as sufficient pain management.  These circumstances are 
exacerbated by the limited access to some medications and the unwillingness of providers 
to prescribe opioids because of fears of abuse and pharmacies that restrict quantities and 
types of certain medications (McNeill, Reynolds, & Ney, 2007).  
Within minority communities approximately 25% of pharmacies have an 
adequate stock of sufficient opioids for pain management, compared with 72% of non-
minority neighborhood pharmacies (Anderson, 2002).  Morrison et al. conducted an 
examination of pharmacies in an urban city, comparing the available stock of sufficient 
opioids in minority and non-minority neighborhoods (2000).  Morrison’s study found that 
51% of the responding pharmacies did not have a sufficient supply of opioids to meet 
patient’s needs; only 25% of those in “non-white neighborhoods” did have an adequate 
supply of opioids to meet patient needs; while 72% of the pharmacies in majority white 
communities had a sufficient supply of opioids (2000). 
 
RECOMMENDATIONS FOR THE TREATMENT OF CANCER PAIN 
 
While cancer is a terminal illness, this is no excuse to refuse patients the opportunity to 
maintain a certain quality of life, free of pain (Nersesyan & Slavin, 2008).  A valid and 
daunting question is what is considered to be adequate pain control? Optimal pain 
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 management is defined as effective if there is a similarity between what the patient 
reports their level of pain to be and the recommended therapy regimen for the relief of the 
pain. The WHO also supports the claim that the recommendations for the treatment of 
cancer pain are vastly inadequate (1996). 
During the course of treatment, clinicians should offer pain education, breakthrough 
opioids for patients receiving long-acting formulations, bowel regimens in patients 
receiving long-acting opioid formulations and confirmation of the coordination of care of 
opioid doses across the health care continuum (Dy et al., 2008). 
Recommendations from the American Pain Society for the improvement of the 
quality of acute and cancer pain management stated that health care settings should 
establish a strong foundation for a coordinated, multilevel systems methodology (Gordon 
et al., 2005).  The routine practices within the health care system should constantly keep 
in mind patient sensitivity to pain, the population served, the type of pain and the 
environment in which the care is provided (Gordon et al., 2005).  This multidimensional 
approach should warrant hasty acknowledgement and treatment of pain, participation of 
patients and families in the pain management plan, improved treatment trends, frequent 
reevaluation and modification of the pain control plan when and if necessary, and 
measurement of processes and outcomes of pain management (Gordon et al., 2005). 
 
CONCLUSIONS 
The ultimate objective of pain control in any patient with a diagnosis of cancer should be 
to optimize the patient’s comfort and function. However, the remaining need for 
improvements in the treatment of chronic cancer pain is evident in the literature and the 
data.  The presented literature highlights remnants of past issues of pain control that 
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 currently plague the medical community. Despite advancements in technology and 
improvement in the quality of care initiatives, opportunities to improve the delivery of 
pain relief and related health outcomes and quality of life remain. 
Overcoming these challenges can be increasingly difficult for individuals who are 
confronted with sociodemographic, geographic, and economic barriers.  These obstacles 
are of great significance and impact the management of pain in patients in rural areas. 
Furthermore, the limited availability of literature specific to this geographic area and the 
role the availability of prescribed pharmaceuticals plays in pain management in rural 
areas only encourages the need to further examine (Kelley, 2007; Robinson, 2009). 
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 Table 2.1 1996-2009 Lung Cancer Incidence Rate (per 100,000 persons) in South 
Carolina counties (South Carolina Department of Health and Environmental Control, 
SCANG, 1996-2009)   
 
South Carolina County Incidence of Lung Cancer  
South Carolina (overall) 32.0 
Abbeville* 30.0 
Aiken* 26.7 
Allendale* 26.4 
Anderson 36.7 
Bamberg* 39.6 
Barnwell* 22.1 
Beaufort* 24.7 
Berkeley 33.9 
Calhoun* 27.1 
Charleston 28.6 
Cherokee* 41.4 
Chester* 39.8 
Chesterfield* 33.2 
Clarendon* 29.0 
Colleton* 43.0 
Darlington* 30.7 
Dillon* 34.9 
Dorchester* 34.5 
Edgefield* 29.6 
Fairfield* 35.5 
Florence 29.5 
Georgetown* 31.0 
Greenville 32.0 
Greenwood* 29.5 
Hampton* 32.1 
Horry 30.6 
Jasper* 27.7 
Kershaw* 41.3 
Lancaster* 32.3 
Laurens* 34.9 
Lee* 
 
30.6 
Lexington 35.2 
McCormick* 22.6 
Marion* 32.5 
Marlboro* 40.2 
Newberry* 34.4 
Oconee* 34.8 
Orangeburg* 29.6 
Pickens* 35.4 
Richland 33.6 
Saluda* 20.3 
Spartanburg 34.7 
Sumter* 30.0 
Union* 41.2 
Williamsburg* 21.8 
York 28.5 
* Indicates counties classified as wholly or partially rural by the Economic Research Service Rural-Urban 
Commuting Areas (RUCA, 2010)
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 Table 2.2 1996-2009 Lung Cancer Mortality Rate (per 100,000 persons) in South 
Carolina counties (South Carolina Department of Health and Environmental Control, 
SCANG, 2009) 
 
South Carolina County Mortality of Lung Cancer  
South Carolina (overall) 58.9 
Abbeville* 58.3 
Aiken* 57.2 
Allendale* 56.2 
Anderson 63.3 
Bamberg* 58.7 
Barnwell* 54.5 
Beaufort* 45.4 
Berkeley 64.8 
Calhoun* 47.3 
Charleston 53.8 
Cherokee* 71.2 
Chester* 71.1 
Chesterfield* 71.2 
Clarendon* 60.1 
Colleton* 70.6 
Darlington* 69.2 
Dillon* 71.3 
Dorchester* 56.0 
Edgefield* 57.7 
Fairfield* 60.7 
Florence 60.8 
Georgetown* 59.0 
Greenville 55.0 
Greenwood* 56.7 
Hampton* 58.8 
Horry 59.3 
Jasper* 50.6 
Kershaw* 65.1 
Lancaster* 61.3 
Laurens* 61.0 
Lee* 
 
70.4 
Lexington 58.9 
McCormick* 55.4 
Marion* 66.4 
Marlboro* 78.1 
Newberry* 60.4 
Oconee* 54.4 
Orangeburg* 51.9 
Pickens* 58.1 
Richland 59.3 
Saluda* 54.1 
Spartanburg 63.9 
Sumter* 57.3 
Union* 67.1 
Williamsburg* 58.6 
York 61.7 
*Indicates counties classified as wholly or partially rural by the Economic Research Service Rural-Urban 
Commuting Areas (RUCA, 2010) 
33 
 
 CHAPTER 3 
RESEARCH DESIGN AND METHODS  
To conduct this secondary data analysis, data was requested from the South 
Carolina Central Cancer Registry and the state’s Medicaid program. Medicaid is a federal 
government eligibility program that provides health insurance coverage for health care 
and other medical services at no cost or at a reduced cost.  Combined, both the Medicaid 
and the Children’s Health Insurance Program (CHIP) enable approximately 60 million 
Americans, including children, pregnant women, parents, seniors and individuals with 
disabilities, to seek needed medical attention (“Medicaid”, 2013). Medicaid is a health 
and long-term care coverage program that is jointly funded by individual states and the 
federal government. Each state establishes and administers its own Medicaid program. 
States are responsible for establishing eligibility criteria within the guidelines outlined by 
the federal government.  However, there are groups that have “mandatory eligibility” 
(“Medicaid”, 2013). South Carolina’s state Medicaid data is housed at the South Carolina 
Department of Health and Environmental Control (SCDHEC).  
 The South Carolina Central Cancer Registry (SCCCR) is a population-based data 
system that assembles information over cancer incidence in the state of South Carolina. 
The compiled data was used to examine trends in prevalence and frequency of cancer in 
defined areas, changes in diagnosis and treatment patterns, and patients' survival rates 
(SCDHEC, 2013). Information on cancer mortality (deaths) is collected by the Division 
of Vital Records and published by the Division of Biostatistics and Division of Public 
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 Health Informatics within DHEC. The SCCCR’s dissemination efforts highlight cancer 
incidence and mortality in the state and nationally.  
Demographic, disease stage, tumor size and grade, cancer therapy and 
prescription variables were requested from the South Carolina Cancer Registry as 
identified by the North American Central Cancer Registry (NACCR, 2010).  This cross-
sectional study examined the impact of geography on medications prescribed for cancer 
pain and its association with survival for South Carolina Medicaid lung cancer patients.  
 
CONCEPTUAL FRAMEWORK 
 
This research was based on Stewart and Teno’s Conceptual Model of Quality of 
Life of Dying Patients and their Families (Figure 3.1).   This model examines the factors 
that impact quality of life, which can be a direct indicator of the quality of care, of 
terminally-ill patients (Stewart, Teno, Patrick & Lynn, 1999). The model developed by 
Stewart et al. evaluates the quality and outcomes of care with three principal classes: 
Patient Factors Affecting Health Care and Outcomes of Care; Structure and Process of 
Care; and Outcomes of Care. 
 
Patient factors affecting health care and outcomes of care include personal and social 
elements. These elements include the patient’s financial ability to seek health care, 
patient race and ethnicity, location standing life situations, clinical diagnosis (severity 
and history), and external support that the patient has access to (marital status).  This 
class also considers support, both clinical 
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 and external This could be viewed as a limitation in rural communities where the 
healthcare system may not offer such support or residents may not be able to access such 
provisions; as well as for those whose personal and social networks do not support health 
needs (Stewart, Teno, Patrick & Lynn, 1999).  These factors directly influence the 
structure and process of care. 
 
Structure and process of care 
 Outcomes of Care are shaped by the structure and process of care. Both structure 
and process are variables that can promote or hamper outcomes.  The structure of the 
health care system can determine access, and eligibility to access services, to the system’s 
organization—the level at which care is provided and support services are made 
obtainable.  These characteristics of the health care system determine health care 
outcomes (receipt of medication, survival, vital status, etc.) on various levels.  The 
system’s organization concentrates on the leadership and the tenets deemed to be 
significant to support the system’s practices (Stewart, Teno, Patrick & Lynn, 1999).  
Access issues and the availability of services can vary depending upon economic 
classifications and geographic limitations.  
 Cancer patients who live in rural areas are forced to receive the majority of their 
medical services from “generalists”, of whom there are shortages of, to treat those with 
such specific needs in these areas (Kelley, 2007). This is an infrastructural component 
that incites concern.  Operationally, the lack of a standard methodology of care that can 
be individualized remains a limitation (Wagner, Austin, von Korff, 1996).  The non-
compliance of clinicians to act in accordance with set recommendations can be attributed 
to inadequate training.  General clinicians are primarily trained to respond to acute 
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 medical needs and diagnose and treat (Wagner, Austin, von Korff, 1996).Yet, clinical 
practitioners in rural areas are forced to attempt to craft their clinical approach to assist 
patients with chronic illnesses who may not have alternative options for medical 
treatment (Wagner, Austin, von Korff, 1996).   
 The Process of Care considers who is delivering the care, the decisions that are 
being made in regards to the patient’s care, supportive services made available to the 
patient and the patient’s family, and the continuation and coordination of health care 
services (Stewart, Teno, Patrick & Lynn, 1999).  In both chronically and terminally ill 
patients, symptom management is an essential part of decision-making. Medications 
prescribed to assist in the alleviation and elimination of related systems are highly 
significant in the quality of life and patient survival. Opioid therapy is necessary for the 
provision of optimal care in cancer patients (Krishna, Poulose, Tan, & Goh, 2010; 
Parsons et al., 2008).
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• Patient and family 
situation 
• Clinical status, 
case-mix 
• Patient  social 
support 
• Family social 
support 
Figure 3.1 Conceptual model adapted from Stewart and Teno’s Model of 
Quality of Life of Dying Patients and Their Families (1999)  
 
*Bolded text in the conceptual model identifies variables analyzed in 
statistical models to address research questions. Patient length of life 
was built into the research design. 
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Outcomes of 
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• Diagnosis and stage 
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• Organization of care 
• Formal support 
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physicians, nurses, 
and caregivers 
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with patient 
• Decision-making 
process  
• Interpersonal and 
communication style  
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Physician 
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• Outpatient care 
• Type of clinical 
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• Length of life 
(Patient & 
family) 
• Length of life 
• Treatment 
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prescribed 
medications) 
• Date of 
diagnosis 
 
• Drug indicator 
 
• Vital status 
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 SAMPLE DESCRIPTION 
 The South Carolina Medicaid sample is composed of women and those who are 
economically eligible for the public health insurance plan. Eligibility for the South 
Carolina public health insurance plan is determined by family size and annual income. To 
be eligible as a Medicaid enrollee with lung cancer, persons must qualify under the 
medically indigent program and the family’s income must not exceed 200% of the 
Federal Poverty Level and personal assets are not allowed to exceed established 
thresholds. The Medicaid data has been linked with data from the South Carolina Central 
Cancer Registry (SCCCR) by the South Carolina Office of Research and Statistics.  This 
linkage verifies all cancer types among the Medicaid patients in the sample by selected 
variables for linkage.  Linkage variables included: patient’s first, middle and last name, 
social security number. This information was not provided to the Investigator and only 
used by the South Carolina Office of Research and Statistics for data linkage purposes. 
 The 1996-2010 linked sample consists of non-Hispanic (NH) black and NH 
white advanced stage (at diagnosis) lung cancer patients (n~19,375) who were enrolled in 
Medicaid having a verified diagnosis in the SCCCR.  Once coding for data analysis post-
inclusion criteria, the analyzed sample was N=1,334. Criteria for being included in the 
analysis sample were: 
1 ) patients had a prescription filled for either an opioid or analgesic through their 
SC Medicaid policy post-diagnosis;  
2) patients had to have been enrolled in South Carolina Medicaid for at least 9 
months prior to the lung cancer diagnosis; and  
3) analyzed patients in the sample only had a primary diagnosis of lung cancer. 
39 
 Clinically stages of cancer are determined by tumor size, quantity of lymph nodes 
impacted, and signs of metastasis. Evidence of metastasis can be found in the bones, 
surrounding organs or the brain.  Stage 4, the most advanced stage of lung cancer, is 
confirmed by the metastasis of the cancer to both lungs, the fluid surrounding the lungs, 
and to other parts body (National Institutes of Health, U.S. National Library of Medicine, 
2013). These cancers were selected because of their high pain prevalence in the later 
stages of the disease and their prevalence in the state of South Carolina (Yoon, 2013; 
Simmons, 2012;Centers for Disease Control and Prevention, National Cancer Institute, 
2010).   
MEASURES 
 South Carolina Medicaid provides health care coverage for approximately 40% 
of children, 58% of the health care for non-elderly women, and has contracts with 82% of 
the state's nursing homes. Medicaid pays for 70% of the people in those facilities and  
provides coverage for the treatment of female breast and cervical cancer according to 
federal screening and diagnosis guidelines and will cover an additional 2,600 cancer 
patients in 2014 as a result of this portion of the fully enacted Affordable Care Act 
(American Cancer Society Cancer Action Network, American Diabetes Association, 
American Lung Association, and Families USA, 2011; National Women’s Law Center, 
2010).  In 2010,  22.5% of South Carolina’s cancer patients were covered by Medicaid. It 
is also possible that some patients are dually enrolled in Medicare (Cancio, Bailey, & 
Mahan). 
 The most most recent data available is 2010—this was especially significant 
with the enactment of the Affordable Care Act and the impending expansion of Medicaid.    
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 Sociodemographic, outcome, and health care infrastructure variables were all included in 
the analyses. In addition, variables reflecting the characteristics of Medicaid enrollees’ 
social support system and socio economic status, the features of the  health care system in 
which they receive their primary cancer treatment, and  outcomes were included for 
demographic purposes. 
DEPENDENT VARIABLES 
 The primary outcomes of interest were the rate of patient survival in the rural 
regions of South Carolina for Medicaid recipients in the advanced stages for lung cancer 
and the receipt of medication.  The relationship between patient survival and analgesic 
treatment, the dependent variables, have been examined in previous research but not 
outside of the palliative care setting and not with regard to specific racial/ethnic groups 
and geographies (Parsons, 2008) in the United States healthcare system in the southern 
state of South Carolina. 
 
INDEPENDENT VARIABLES 
 Characteristics and variables that impact the manner in which pain is managed 
was examined. Patient factors affecting health care and outcomes of care (i.e. marital 
status, race and ethnicity, and gender), the structure and process of care (provider county 
and declared specialty of the provider), and outcomes of care (i.e. date of diagnosis and 
vital status) characteristics and the impact of these social, environmental, and economic 
factors on the management of pain in rural, Medicaid-eligible lung cancer patients were 
included in the analysis, and controlled where needed. While the independent variables 
that considered patient stage of lung cancer and survival time in months were not listed in 
the conceptual model, they were built into the research design and were analyzed.
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 Patient factors affecting health care and outcomes: 
Family social support 
o Patient gender 
o Race/ethnicity - Non-Hispanic black and Non-Hispanic white 
o Marital status - married or single/divorced/separated.  This variable was defined 
as the social and emotional support received from a patient’s spouse. 
Patient and family situation 
o South Carolina rural/urban residents – use of Urban Influence Codes and 
urban/rural continuum in non-metropolitan counties.  
 
Clinical Status/ Case mix 
o Patients diagnosed with Stage 4 lung cancer- This can greatly impact the 
longevity of life as well as clinical treatment. 
 
Structure and Process of Care: 
 
Access to and the process of care delivered by clinicians within the organization of 
care 
 
o Provider county – use of Urban Influence Codes and urban/rural continuum in 
non-metropolitan counties to identify the urbanicity or rurality of the managing 
provider’s county 
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 o Provider type/specialty – the managing provider who was the primary provider of 
oncologic care (i.e., cancer pain treatment) 
 
 
Technical process with patient and formal support services available 
o Primary diagnoses – patients having a primary diagnoses of cancer and available 
ICD-9 codes that indicate comorbidities 
o Therapeutic class of drug – drug identified as being an opioid 
 
Outcomes of care 
o Cancer therapy – treatment being provided outside of prescribed opioids, 
chemotherapy and radiation 
o Vital status – was the Medicaid recipient alive or dead 
 
DATA COLLECTION PROCEDURES 
South Carolina Medicaid’s database is comprised of variables that provide 
demographics, economic circumstances, and claim and reimbursement codes for health 
care services provided to individuals enrolled in the program, diagnoses of diseases and 
laboratory services. This data was available upon request from the South Carolina Office 
of Research and Statistics. 
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 The South Carolina Central Cancer Registry (SCCCR) is a population-based data 
system that assembles information over cancer incidence in the state of South Carolina. 
The compiled data was used to examine trends in prevalence and frequency of cancer in 
targeted areas, changes in diagnosis and treatment patterns, and patients' survival rates 
(SCDHEC, 2013). Information on cancer mortality (deaths) is collected by the Division 
of Vital Records and published by the Division of Biostatistics and Division of Public 
Health Informatics within DHEC. The SCCCR’s dissemination efforts highlight cancer 
incidence and mortality in the state and nationally.  
Upon receipt of Institutional Review Board approval from the University of South 
Carolina data applications were submitted to the Institutional Review Boards of the South 
Carolina Department of Health and Environmental Control, and the South Carolina 
Central Cancer Registry. Once data applications were approved, the South Carolina 
Office of Research and Statistics began to link the requested variables and the data was 
provided to the Principal Investigator in a password protected file. Data linkage occurred 
using unique identifiers: year of birth, last name, and social security number.  Desired 
data was extracted from South Carolina Medicaid claims filed by enrolled late stage lung 
cancer patients.  Rural/urban geography was assigned using rural/urban continuum codes.  
These codes distinguish non-metropolitan counties by level of urbanization and proximity 
to metropolitan areas. 
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 AIMS AND HYPOTHESES 
The outlined study addressed two primary aims. 
Aim #1 –To examine patient residence as a factor associated with the receipt of  
prescribed opioid therapy among SC Medicaid lung cancer patients. . 
Hypothesis: Rural patients will be less likely to receive opioid therapy. 
Outcome: Receipt of opioid therapy 
Covariates: Stewart and Teno’s model components (Figure 3.1) 
Analysis: Bivariate analysis and Logistic regression  
 
Aim # 2 – To assess the association between patient residence and the survival 
rate of distant stage lung cancer patients, considering the receipt of opioid 
therapy. 
Hypothesis: Rural patients will experience a decreased survival rate and will be 
less likely to be prescribed opioid analgesics. 
Outcome: Patient survival rate  
Covariates: Stewart and Teno’s model components (Figure 3.1) 
Analysis:  Bivariate analysis and Cox proportional hazard survival model 
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 ANALYSIS 
 Using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) all of the following 
statistical analyses were conducted.   
Aim 1 examined the relationship between the geographical association of the lung cancer 
patient and the receipt of a prescription for opioids. The outcome of interest was the 
receipt of opioid therapy for lung cancer patients among rural non-Hispanic white 
Medicaid recipients and rural non-Hispanic African-American Medicaid recipients after 
controlling for other demographics and type of cancer therapy.  Because the two groups 
of recipients were being compared on a ratio outcome, univariate and bivariate analyses 
were conducted to obtain the descriptive properties of the sample. The bivariate analysis 
allowed cross tabulations to examine the trends and differences in patient factors 
affecting health care and outcomes of care, structure and process of care, and outcomes of 
care the prescribing of opioids and analgesics.  In addition, the bivariate analysis was 
performed using chi-square to ascertain significance among the outcome variable and 
stated covariates.  
 Logistic regression analysis was conducted to assess associations between receipt 
of opioid analgesics and race/ethnicity, marital status, gender, patient county and the 
presence of cancer specialists. The outcome of the logistic analysis was a dichotomous 
measure of whether or not the patient was prescribed an opioid analgesic or received no 
medication. 
Aim 2 assessed the association of patient geographical residence on the survival rate for 
distant stage lung cancer patients among SC Medicaid enrollees. The primary outcome of 
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 interest was patient survival.  Patient deaths were identified as cancer-related deaths or 
non-cancer related deaths. A descriptive, bivariate analysis was performed to determine 
the associations between patient factors affecting healthcare outcomes of care, the 
structure and process of care, and the outcomes of care for late stage lung cancer patients 
enrolled in South Carolina Medicaid.  A survival analysis using Cox’s proportional 
hazard model was used to calculate the survival rate, in months, from the primary cancer 
diagnosis to death, the event of interest.   
The primary objective of the planned research was to investigate the association 
between geography and patient survival in relation to prescribed opioid medications for 
lung cancer patients. The impact of prescribed medications, opioids, on the longevity of 
patient life meeting and exceeding the average survival rate, while controlling for cancer 
therapy and other demographics, was the primary outcome of interest. In the principal 
analyses, adequate receipt of patient survival was measured according to prescribed 
opioid medication and dosage of prescribed opioid medication, after controlling for 
demographics and cancer therapy.  
Descriptive data and results for the analyses is presented in two prepared 
manuscripts that constitute Chapter 4.  These manuscripts will be composed and 
formatted for submission to two peer-reviewed journals (The Journal of Rural Health and 
Journal of Pain). Chapter 3 has presented the research design for the study, along with an 
outline of the methodology and statistical analyses.
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 CHAPTER 4 
RESULTS 
Chapter 4 presents findings of the conducted data analysis plan as designed in 
Chapter 3 in the form of two manuscripts. Manuscript #1 examines the relationship 
between urban and rural patient geography and prescription medications intended to 
alleviate pain among late stage lung cancer patients in South Carolina who are enrolled in 
Medicaid.  Manuscript #2 investigates the influence of receipt of pain medication on the 
patient survival rate of late stage lung cancer patients of South Carolina who are enrolled 
in Medicaid. 
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 MANUSCRIPT #1 
RACE AND GEOGRAPHICAL BARRIERS TO PAIN MEDICATION IN LATE 
STAGE LUNG CANCER PATIENTS1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Magwood, J.S., Wigfall, L.T., Adams, S.A., Norris, L., Probst, J., & Glover, S.H. To be 
submitted to Journal of Rural Health
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 Abstract: 
Purpose: The barriers that prevent rural populations from receiving appropriate 
medication treatment are greater than geography. Obstacles range from a lack of 
availability of needed medications and providers to increasingly strict prescription 
regulatory policy   However, the existence of these barriers is especially true for rural 
residents with chronic conditions like lung cancer, a high-pain disease, who may not be 
able to access specialty care. Pain that results from lung cancer needs to be treated with 
medications meant for reduction and alleviation—opioids and analgesics.  This study 
examined the prescribing practices of physicians and late stage lung cancer patient’s level 
of accessibility to medications commonly prescribed for pain among residents of rural 
and urban geographies. 
Methods: Data for the analysis was requested from the South Carolina Central Cancer 
Registry and linked with South Carolina Medicaid data. A bivariate and logistic analysis 
was conducted using SAS 9.4 to examine patients who received a single or combination 
prescription for opioids or analgesics and those who were not prescribed either.   
Findings: In the sample of 1,334 late stage lung cancer patients, there was no statistically 
significant evidence that our target race and ethnicities or residents of particular 
geographies were more or less likely to be prescribed pain medications.  When the patient 
factors and the structure and process factors impacting health care were examined, all 
variables and relationships were statistically similar.
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 Conclusions: Presented barriers only sustain the existence of health disparities, 
geographically and racially and potentially impact the method of treatment for patients as 
well as the type and frequency at which pain medications are prescribed.  Demands for 
changes in local and national policy that monitor the accessibility to pain medication in 
rural communities is necessary, even if to simply insure the availability of an adequate 
amount of medication. 
Introduction Population health is defined as “an approach [that] focuses on interrelated 
conditions and factors that influence the health of populations over the life course, 
identifies systematic variations in their patterns of occurrence, and applies the resulting 
knowledge to develop and implement policies and actions to improve the health and well-
being of those populations.”1,2 The levels of variation that exist in health care 
accessibility for urban and rural populations are greatly dependent upon many 
determinants that heavily impact health care outcomes.  Beyond adequate accessibility, 
existing policies and regulations can also be a hindrance. These are obstacles that some 
healthcare systems, specifically rural, may not have the means to overcome.  
Descriptions of rural populations and regions entail increased elderly and 
children, flailing employment rates, financially disadvantaged, and uninsured and 
underinsured residents.3,4 Providers practicing in these environments often bear the brunt 
of  these circumstances. Moreover, rural providers must have the ability to adapt when 
the clinical workforce is lacking, specifically specialists.3-5 This needed adaptation is 
equally true for the pharmacies located in rural areas. Rural demographics have an 
increased need for pharmacy services.6 Pharmaceutical care is a critical part of the 
healthcare continuum. In rural areas, pharmacists are health care providers who take on a 
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 larger role as one of few accessible health care providers. This adds to the challenges that 
rural pharmacies encounter and poses a threat to the health outcomes of the community.   
These are the types of challenges that influence late stage lung cancer patients 
residing in rural areas—they are greater than medication affordability. Seventy-five 
percent of advanced stage cancer patients suffer with moderate to severe pain; and 25-
30% of cancer patients in the advanced phases experience severe pain.7 Opioids and  
analgesics are the principal medications prescribed for pain relief in cancer patients.8,9  
However, the possibility of limited access to pharmacists, primary care providers and 
cancer specialists, may prevent late stage lung cancer patients who need pain 
management medications, opioids and analgesics, from receiving them. It is necessary to 
understand who is receiving pain medications and where patients are seeking care. For 
this study’s purpose, greater accessibility of patients to providers and medications were 
defined according to the quantity of clinical providers (cancer specialists) in the defined 
geographical areas, urban or rural, as well as the specific medications prescribed. Patient 
Factors Affecting Health Care and Outcomes of Care; Structure and Process of Care; and 
Outcomes of Care influences were examined to determine impact on patient receipt of 
medication. The research question this study sought to answer was whether patient 
geography influenced the type of pain medications late stage cancer patients were 
prescribed. 
 
Methods 
Expedited approval from the University of South Carolina Institutional Review 
Board was received to examine data from the South Carolina Central Cancer Registry 
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 and South Carolina Medicaid for this cohort study. Patient data was requested from the 
South Carolina Cancer Registry for South Carolina Medicaid recipients who had been 
diagnosed with late stage lung cancer (stage 4) from 1996-2010.   Data was then 
transferred to the South Carolina Office of Research and Statistics to be linked with 
South Carolina Medicaid data. Requested variables for the total population included 
demographic variables on patients and providers, rural-urban commuting area (RUCA) 
codes, and patient claims information. 
Study Population The study sample was composed of 1,334 South Carolina 
Medicaid recipients who were diagnosed with late-stage lung cancer. Patients included in 
the sample had to have filled a prescription for either an opioid or an analgesic. These 
specific drug classes were selected because of their primary use for the alleviation of pain 
with high pain diseases, like lung cancer, and other ailments.  Ethnicities and races 
included in the analysis were Non-Hispanic Whites and Non-Hispanic Blacks identified 
as residents of urban and rural regions of South Carolina. 
Dependent Variables The primary outcome variable examined was receipt of 
either an opioid or analgesic for patients with late stage lung cancer.  The receipt of 
medication variable was dichotomized: 1) patients who were prescribed either an opioid 
or analgesic, and 2) patients who were prescribed neither and opioid or analgesic.  
Independent variables Main independent variables were: race/ethnicity of 
patients (Non-Hispanic White, Non-Hispanic Black), residence of patients (rural or 
urban), physicians serving the patient (cancer specialists), and pharmacists. Geography of 
each exposure variable was defined using rural and urban continuum codes assigned by 
the United States Department of Agriculture’s Economic Research Service (USDA). 
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 USDA uses these classification codes to distinguish metropolitan and non-metropolitan 
counties.8 For the purpose of the study, urban was defined as central and neighboring 
counties of metropolitan regions where the population is 1,000,000 or more and counties 
in metropolitan regions made up of less than 250,000 to 1,000,000 residents. Criteria for 
rural regions were: 1) an urban population of 20,000 or more bordering or not bordering a 
metropolitan area, 2) an urban populace of 2,500-19,999, bordering or not bordering a 
metropolitan area, or 3) wholly rural (not having a population of 2,500 or more) 
bordering or not bordering to a metropolitan area. 
Covariates Patient factors affecting health care and outcomes of care include 
gender and marital status of patients (single, separated or divorced or married); structure 
and process of care (presence of cancer specialists and primary care providers); and 
Outcomes of Care (patient vital status, receipt of medication (frequency) influences were 
assessed for the possibility of confounding. 
The structure and process of care component of the analysis measured the 
presence and location of cancer specialists and other primary care providers. The 
presence and location of each type of provider was assessed to examine the potential 
influence of provider type on patient access to care and receipt of pain medication. 
Cancer specialists were grouped as providers who specialized in: pulmonary medicine, 
oncology, radiology (diagnostic and therapeutic), internal medicine, and thoracic surgery; 
clinical disciplines which commonly provide medical treatment to lung cancer patients. 
Statistical Analyses Univariate (Table 4.1) and bivariate analysis were 
performed to obtain the descriptive properties of the sample population. The bivariate 
analysis allowed cross tabulations to examine the trends and differences in patient factors 
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 affecting health care and outcomes of care, structure and process of care, and outcomes of 
care the prescribing of opioids and analgesics.  In addition, the bivariate analysis was 
performed using chi-square to ascertain significance among the outcome variable and 
stated covariates.  
 Logistic regression analysis was conducted to assess associations between receipt 
of opioids or analgesics and race/ethnicity, marital status, gender, rural/urban county and 
the presence of cancer specialists. The outcome of the logistic analysis was a 
dichotomous measure of whether or not the patient was prescribed an opioid analgesic or 
neither. 
Results 
 From a sample of 1,334 patients, 561 were prescribed an opioid analgesic while 
773 were not. Of the 1,334 sample patients, 679 were Non-Hispanic Black and 636 were 
Non-Hispanic White. Patients identified as “Other” (n=19) were excluded from the 
analysis because of the potential of the small sample size to influence accuracy of the 
data.  A larger proportion of sample patients resided in the urban region of South 
Carolina (n=899) than the rural areas (n=435).  Considering gender, males composed 
58.5% of the sample, while there were a lesser percentage of females, 41.5%.   In 
addition, patients who were single, separated, separated, or divorced represented 39.8% 
of the variable considering marital status, while 25.4% of this sample was married.  
Sample characteristics from the study period when both race and ethnicity and geography 
are considered are described in Table 4.1. 
The only statistically significant variable when medication receipt was analyzed 
was the location of the primary care provider patient location combination (p=0.02).  The 
rural patient, rural provider combination was present for 28.8% of persons studied, while 
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 the urban patient, urban provider encounter combination was present for 51.4% of 
persons examined.  Rural patient encounters with primary care providers in urban regions 
accounted for 1.8% of patient-provider encounters with primary care physicians. Within 
the sample, there were a total of 374 cancer specialists (Table 4.2). Cancer specialists had 
a greater presence in the urban geography. Also in the urban geography, the urban 
pharmacy, urban patient combination resulted in a greater amount of filled prescriptions.  
The logistic regression examining receipt of analgesics and opioids is shown in 
Table 4.3. All analyzed associations were not statistically significant, demonstrating that 
none of the analyzed factors were direct factors related to patients’ receipt of pain 
medication.  Logistic results were statistically similar for all patient factor variables—
patient county, race and ethnicity, and patient gender.  Examining Structure and Process 
of Care also showed no statistically significant difference among considered variables. 
 
Discussion 
 
The results of the analysis reflected that none of the analyzed factors were 
statistically significant in showing the likelihood of pain medications being prescribed to 
either urban or rural populations as well as the different races and ethnicities considered. 
Within the data, rural persons prescribed pain medications composed less than half of 
those prescribed medications. Though not as extreme, this disparity was also present 
among the two races. Non-Hispanic Whites received more prescriptions than the Non-
Hispanic Blacks.  The disparity in the quantity of and to whom medications are dispensed 
among late stage lung cancer patients is supported by literature that speaks to the 
disparity in cancer pain management, especially among the minority race and rural 
geographical regions.11,12  
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 Among the population of persons receiving medication, less married persons 
were prescribed pain medications than those who were single, separated, or divorced 
persons.   
This could be a reflection of the emotional and support system that is readily 
available to married persons. Published research makes the connection between 
emotional and instrumental support.13 This support system is related to increased mental 
health and quality of life.13 Similar research also provides evidence that the psychological 
support from spouses result in improved outcomes for cancer patients.14 In addition, 
because the number of persons whose marital status was not reported was high in 
comparison to the sample size of those prescribed medications, a “not reported” variable 
was created to ensure that this data was captured. Creating this variable was key because 
of the potential for this missing data to skew the results during analysis. 
For the rural patient, primary care provider combination variable, the increased 
quantity of patient’s receiving medication from primary care providers could be related to 
patient distance and greater accessibility to primary care providers. This could be 
associated to providers’ awareness of patient’s limited accessibility to healthcare which 
encourages them to more readily prescribe to rural patients.  A second reason for this 
could be patient’s sole access to healthcare is to seek care from this type of provider.  
Lastly, the current data also showed a lack of cancer specialists in the rural 
region of South Carolina. Approximately 72% of the patient sample did not have an 
interaction with a cancer specialist, a clear issue of inadequate access to healthcare 
services (Table 4.3). 
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 Limitations An encountered limitation of this study was the level of missing 
and unavailable data.  This is often common with secondary data analyses in which 
investigators rely upon data compiled by agencies and organizations. A second limitation 
was the selected sample of patients who commonly experience less than adequate 
healthcare could have possibly impacted data outcomes, those who makeup vulnerable 
and disparate populations already pre-existed. A third limitation was the use of a 
homogenous Medicaid sample of patients. However, this was also viewed as a strength 
because of the reliability of data accuracy and a defined population who were covered 
under target public health services. 
Conclusion 
In 2014 there was an estimated 26, 390 new cancer cases in the South Carolina; 
4,130 of those new cases were lung cancer cases.18 Patients who do not receive 
appropriate medications that assist in the relief of pain must endure a diminished 
quality of life.15,16  Previously published literature and provided data showed that 
decreased percentages of the minority race and geographic location of patients are 
barriers that disproportionately affect the percentage of rural patients who receive 
medication.   Such barriers only sustain the existence of health disparities, geographically 
and racially.  Demands for changes in local and national policy that monitor the 
availability of pain medications in rural communities are necessary, simply to ensure 
availability of adequate amounts. Increasing pain medication accessibility for certain 
populations raises concerns for patient abuse or the diversion of medications.  One 
manner to combat this is the appropriate use of prescription monitoring programs.  Not 
only should the use of these prescription monitoring programs be mandated, but also 
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 requiring the utilization of systems that have the ability to communicate with one another 
is imperative. Lastly, incentivizing pharmacies to establish themselves in rural and 
minority communities is essential to the provision of quality healthcare and the healthcare 
continuum.17    
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 Table 4.1. Factors associated with receipt of opioid analgesic pain medications  
 Total 
N (%) 
Opioid/Analgesic 
receipt N (%) 
No pain 
medication 
N (%) 
p  
(opioid 
receipt) 
Total 1334 
(100.0) 
561 (100.0) 773 (100.0)  
     
Patient Factors      
Residence     
   Rural  435 (32.6) 171 (30.5) 264 (34.2) 0.33    Urban 899 (67.4) 390 (69.5) 509 (65.8) 
     
Sex     
   Male 780 (58.5) 313 (56.8) 467 (61.4) 0.29    Female 554 (41.5) 248 (44.2) 306 (39.6) 
     
Race1     
   Non-Hispanic Black 679 (50.1) 268 (47.7) 411 (53.2) 0.13    Non-Hispanic White 636 (47.7) 288 (51.3) 348 (45.0) 
     
Marital status2     
   Single/Separated/Divorced 531(39.8) 223 (39.8) 299 (38.7) 
0.82    Married 339 (25.4) 144 (25.7) 187 (24.2) 
   Missing 464 (34.8) 191 (34.0) 273 (35.2)  
     
Structure and Process of Care     
     
Cancer specialist location     
   Rural patient, rural MD 63 (4.7) 21 (3.7) 42 (5.4) 
0.57    Rural patient, urban MD 24 (1.8) 11 (2.0) 13 (1.7)    Urban patient, rural MD 20 (1.5) 9 (1.6) 11 (1.4) 
   Urban patient, urban MD 267 (20.0) 123 (22.0) 144 (18.6) 
     
Primary care provider location     
   Rural patient, rural MD 384 (28.8) 149 (26.6) 235 (37.8) 
0.02    Rural patient, urban MD 46 (3.4) 21 (3.7) 25 (3.2)    Urban patient, rural MD 195 (14.6) 94 (16.8) 101 (13.1) 
   Urban patient, urban MD 685 (51.4) 291 (52.1) 394 (51.0) 
     
Pharmacy location4     
   Rural patient, rural pharmacy 392 (29.4) 158 (28.2) 234 (30.3) 
0.34    Rural patient, urban pharmacy 36 (2.7) 11 (2.0) 25 (3.2)    Urban patient, rural pharmacy 76 (5.7) 38 (6.8) 38 (4.9) 
   Urban patient, urban pharmacy 799 (59.9) 336 (59.9) 463 (59.9) 
1 19 patients removed from the Race variable to the “Other” race and ethnicity 
2 191 marital status missing from patients prescribed medications. 273 marital status missing from patients not prescribed medications. 
34 patients missing from Primary care physician/patient variable 
431 total patients missing from pharmacy location, 18 from those prescribed and 13 from those not prescribed pain medication 
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 Table 4.2. Quantity of South Carolina cancer specialist by geographical region 
 Urban Rural 
Cancer Specialists 291 83 
 
Table 4.3. Adjusted Odds for receipt of opioid pain medications for distant stage 
lung cancer patients (N=1334) 
 Adjusted OR 
 (95% CI) 
Unadjusted OR 
(95%CI) p-value
1 
Intercept 0.25 (-3.48, 0.76)  0.66 
    
Patient Factors    
Residence    
  Rural  0.83 (0.29-2.38) 1.46 (0.89-2.40) 0.73 
  Urban  (ref) 1.00 1.00  
    
Sex    
  Male   (ref) 1.00 1.00  
  Female  1.23 (0.79-1.91) 1.13 (0.75-1.73) 0.36 
    
Race    
  Non-Hispanic Black 0.86 (0.55-1.33) 0.75 (0.50-1.15) 0.49 
  Non-Hispanic White (ref) 1.00 1.00  
    
Marital status    
  
Single/Separated/Divorced 1.29 (0.46-3.65) 
0.89 (0.54-1.48) 
0.63   Married (ref) 1.00 1.00 
  Missing  0.73 (0.41-1.30) 0.77 (0.45-1.32) 
 
Structure and Process of 
Care: 
Cancer specialist location    
   Rural - 0.66 (0.40-1.10) 0.99    Urban (ref) - 1.00 
    
PCP location2    
   Rural 0.74 (0.29-1.87) 0.62 (0.39-1.01) 0.52    Urban (ref) 1.00 1.00 
    
Pharmacy location    
  Rural  1.73 (0.44-6.78) 0.61 (0.36-1.01) 0.43   Urban (ref) 1.00 1.00 
1p-value of Adjusted Odds Ratio 2Primary care provider location
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 Abstract:  
Health care inequities faced by rural residents of South Carolina span the breadth of all 
clinical diagnoses. Inequalities in cancer care and outcomes, in particular those 
encountered by rural residents, include the shortage of qualified clinicians to treat cancer 
patients, a fragmented continuum of care, and a lack of evidence to effectively guide and 
identify the placement of administrative and clinical resources in South Carolina’s rural 
regions. The deficit of clinical resources refers to a lack of cancer specialists to treat and 
prescribe medications appropriately as well as pharmacies to fill prescriptions.   Each of 
the highlighted inequalities has the potential to not only impact the manner of health care 
treatment but also has the potential to influence the longevity of a patient’s life.  The 
conducted survival analysis to determine the impact of these factors on the rate of patient 
survival for those with distant stage lung cancer found that gender was statistically 
significant in the survival of patients (AHR=1.31, CI:1.03-1.65). This study sought to 
determine the geographical disparities in the prescribing of pain medications for Non-
Hispanic Whites and Non-Hispanic Blacks and the impact of observed patient factors on 
patient’s survival rate among late stage lung cancer patients enrolled in Medicaid.   
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 Introduction  
The geography and demography of South Carolina’s rural regions create 
difficulties for residents who require health care. For these exact reasons, it is also 
difficult to attract health care providers, having a direct impact on health care outcomes 
and the increasing prevalence of health disparities.1,2  The inability of rural areas to 
recruit and retain both primary care physicians and specialists greatly influences the level 
of  care received by patients with chronic conditions, like lung cancer. Exacerbating 
circumstances for advanced stage lung cancer patients experiencing pain is the decreased 
likelihood of a rural pharmacy’s inventory to contain an adequate supply of medications 
commonly prescribed to address cancer pain. 3-5 
Nationally, lung cancer is the most frequently diagnosed cancer and is the leading 
cause of cancer death. The American Cancer Society predicted, by the end of the year 
2014, approximately 1,665,540 incidences of lung cancer.6 Cancer related deaths, lung 
cancer included, are directly associated with time of diagnosis and stage of disease at 
diagnosis.  For residents of rural areas this can pose specific barriers.  Mounting evidence 
confirms that the demographic of South Carolina’s rural communities are  more likely to 
be composed of racial minorities and persons of a lower socioeconomic status—variables 
that not only increase the risk of being diagnosed with cancer but also being diagnosed at 
a later stage with inferior outcomes.3   
 Poor individuals that reside in rural areas are also more likely to be either 
uninsured or underinsured than inhabitants of urban areas. This lack of coverage limits 
access to healthcare and needed medications.3  In addition to patients not being able to 
afford medications, pharmacists and pharmacies in rural areas may not stock opioids and 
analgesics, medications commonly used for pain, because of safety and cost concerns.7  
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 More specifically, within minority communities approximately 25% of pharmacies have 
an adequate stock of sufficient opioids for pain management, compared with 72% of non-
minority neighborhood pharmacies.8   Morrison et al. examined pharmacies in an urban 
city, comparing the available stock of sufficient opioids in minority versus non-minority 
neighborhoods.9  Study results indicated that 51% of the area’s pharmacies did not have a 
sufficient supply of opioids to meet patient’s needs; only 25% of those in “non-white 
neighborhoods” had an adequate supply of opioids to meet patient needs; while 72% of 
the pharmacies in majority white communities had a sufficient supply of opioids.9 The 
absence of needed medications to address cancer pain worsens the scenario for rural 
populations.  
Pain is the symptom most commonly associated with lung cancer as it is 
experienced by 70-80% of advanced stage cancer patients at varying levels.3-5,10 Cancer-
related pain has been directly associated with reduced patient survival.11,12 Because the 
occurrence and incidence of cancer is increasing, cancer pain should be expected and 
attended to as soon as possible instead of at later stages of the disease.13 However, 
constant barriers continue to present themselves for rural regions and prevent immediate 
attention to the disease and its symptoms, impacting patient survival, the potential 
intensity of pain, as well as overall patient health outcomes. 
To address whether or not opioids and analgesics influence the rate of patient 
survival and whether or not rural populations experience a reduced survival rate as a 
result of medication receipt, this study explores the relationship between rural residence, 
patient survival, and the receipt of medication to manage pain in a population of 
advanced stage lung cancer patients enrolled in South Carolina Medicaid
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 METHODS 
Data: Study data was requested from the South Carolina Central Cancer 
Registry (SCCCR). Data from SCCCR was linked by the South Carolina Office of 
Research and Statistics (ORS) with South Carolina Medicaid claims data using patient 
identifiers assigned by the ORS (Office of Research and Statistics). Data is provided to 
SCCCR by South Carolina hospitals (registry and non-registry), pathology laboratories, 
treatment centers, and physician offices.  SCCCR’s database is not only representative of 
cancer incidence in South Carolina but also contains patient demographics and clinical 
data pertaining to each specific cancer case, changing trends in diagnosis and treatment, 
and patient survival rates.14  
Cohort description:  The study sample was composed only of South Carolina 
Medicaid beneficiaries who were diagnosed with lung cancer between the years 1996-
2010.  From this sample of lung cancer patients, only late stage lung cancer patients who 
were continuously enrolled in Medicaid for at least 9 months prior to diagnosis were 
included in the sample. For all patients, lung cancer was the first primary cancer 
diagnosis. Patients with a secondary malignancy were excluded from the analysis. Patient 
data was right-censored (those not experiencing the event of interest (death) for the study 
duration were not analyzed), to avoid bias in the survival analysis. For inclusion in the 
post-diagnosis population, patients had to have 1) had a prescription filled for either an 
opioid, analgesic, or both through their SC Medicaid policy post-diagnosis; 2) been 
enrolled in South Carolina Medicaid for at least 9 months prior to the lung cancer 
diagnosis; and lung cancer was the primary malignancy.  
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 Patient geographic information was assigned using rural-urban commuting area 
(RUCA) codes.  RUCA codes classify United States census tracts using measures of 
population density, urbanization, and daily commuting. These classification codes 
allowed for the identification of  the geography of patient’s location , urban or rural, 
according to  assignments made by the United States Food and Drug Administration 
Economic Research Service.15 To learn more about prescribing practices in rural areas, 
physician location and pharmacy location were also described as urban or rural using the 
RUCA codes. Each pharmacy and medical claim was linked with the patient’s assigned 
ORS identifier to provide geographic data. 
 
Measures 
Conceptual framework: Stewart and Teno’s Conceptual Model of Quality of 
Life of Dying Patients and their Families (Figure 4.1) was adapted to assess the variables 
that impact quality of healthcare received by terminally-ill patients, which is directly 
correlated to patient healthcare and healthcare outcomes.16 The model evaluates the 
quality and outcomes of care with three principal classifications: patient factors affecting 
health care and outcomes of care; structure and process of care; and outcomes of care. 
The selected model conceptualizes health service utilization, the quality of patient care, 
and healthcare outcomes. The model is used as a measure of assessing patient quality of 
care and end-of life care. 
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Patient Factors Affecting Healthcare and Outcomes of Care The personal 
and social environments of patients impact health care utilization and outcomes. 
Examined personal and social environments included patient race/ethnicity (Non-
Hispanic Black, Non-Hispanic White, and other), gender, marital status (single, married, 
separated or divorced), and patient geographical residence (urban/rural). Race/ethnicity, 
patient geographical residence, and gender influence the manner in which patients receive 
healthcare and are determinants in the availability and utilization of health care.7-9, 17 The 
support system offered by marriage has also been shown to impact patient outcomes.18 
Marital status was operationalized as single, married, or separated/divorced. Patients at a 
specific stage of lung cancer was built into the data request; therefore a part of the 
research design. 
Structure and Process of Care Patients within the dataset were all Medicaid 
patients. Patient enrollment in the same insurance program with the same eligibility 
Patient Factors 
Affecting 
Healthcare and 
Outcomes of Care 
Structure and Process 
of Care Outcomes of Care 
• Marital Status 
• Race/ethnicity 
• Regional 
location 
(urban/rural) 
• Primary cancer 
diagnoses 
 
• Provider county-
Pharmacy and 
Physician 
(urban/rural) 
• Provider 
type/specialty 
 
• Date of 
diagnosis 
• Drug indicator 
• Vital status 
Figure 4.1. Conceptual model adapted from Stewart and Teno’s ‘Model of Quality of Life of 
Dying Patients and Their Families (1999)  
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 requirements, indicates similar levels of affordability and accessibility to health care, 
presumably. Establishing inclusion criteria that all patients were continuously enrolled in 
Medicaid for at least 9 months prior to diagnosis insured that there was not a break in 
health insurance coverage and that a lack of health insurance was not the patient’s 
primary reason for not receiving medical care sooner.  
 Geographic location (urban/rural) was coded using rural urban commuting codes 
for all physicians (cancer specialists and all other physicians in the sample) and 
pharmacists by whom Medicaid claims were filed. The geography of providers 
(physicians and pharmacists) have an effect on patient access to healthcare.   Patient 
diagnosis is also impacted by access to care. For all patients, lung cancer was the first 
cancer diagnosis. Considering only the first cancer diagnosis reduced the influence of 
previous or post diagnoses in patient care, cancer staging in the current diagnosis and 
prognosis, and cancer progression.   
Outcomes of Care The patient sample considered only patients who received 
pain medications commonly prescribed for cancer patients, opioids and analgesics. The 
patient survival rate was assessed from the point of the patient’s primary diagnosis. 
Survival rate was assessed for cancer related deaths. Patients not experiencing the event 
of interest, death, were censored post December 2010. Patient survival time in months 
was calculated from the date of diagnosis to the point of death for all patients 
experiencing death.  This was examined in the Cox Proportional Hazard survival model. 
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 Statistical Analysis A descriptive, bivariate analysis was performed to 
determine the associations between patient factors affecting healthcare outcomes of care 
and the structure and process of care. A survival analysis using Cox’s proportional hazard 
model was used to calculate the period from the primary cancer diagnosis to death.  Cox 
proportional hazard model is defined as follows: 
Hi(t)=λ0(t)exp{β1xi1+…+βkxik}. 
As modeled, the hazard of death for individual (i) at time (t) is the result of baseline 
hazard function (λ0(t)) and linear function of a set of defined covariates(k) making up the 
components of the described conceptual model: patient factors affecting healthcare 
outcomes of care, the structure and process of care, and the outcomes of care previously 
described.19 These covariates of the conceptual model are expressed through the xik 
function of the Cox model. 
 
Results 
Within the sample of 1,334 of late stage lung cancer patients, 561 were 
prescribed either an opioid or analgesic, while 773 patients did not receive opioid 
analgesic medications. In the sample 32.6 % (n=435) resided in rural South Carolina and 
67.4% (n=899) resided in urban areas of South Carolina. More than half of the study 
sample was male (58.5), while exactly half of the study sample were Non-Hispanic 
Blacks (50.1). Results from the descriptive analysis are reported in Table 4.4.  
 To begin examining patient survival and death, a bivariate analysis of patient 
factors and health care system process factors was performed. There was a total of 1, 293 
cancer-related patient deaths. Of these cancer deaths, 561 were persons that had received 
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 prescriptions for opioids or analgesics, which was not statistically significant (Table 4.5). 
Of those who were prescribed opioids or analgesics, 97.3% experienced death while 
96.5% of those who were not prescribed opioid analgesics died a cancer-related death. 
Presented data also shows a greater percentage of cancer deaths were within the urban 
population (65.8). Also in the sample a greater number of males died, while a greater 
number of females survived. Similarly, more Non-Hispanic Whites survived than Non-
Hispanic Blacks. Race and ethnicity were statistically significant in the bivariate analysis 
of cancer related deaths. Though patient marital status was not statistically significant, 
more single, separated, and divorced persons experienced cancer-related deaths than 
married persons. 
Considering the process and structure of patient care, the location of primary 
care providers was a statistically significant factor. The rural primary care provider, rural 
patient combination variable composed 97.4% of the deaths of among primary care 
provider patient encounters. The urban patients, urban primary care provider combination 
variable made up over half (7.3) of the sample of cancer deaths for this group as well. 
This result was also true for the urban pharmacy, urban patient combination variable 
(96.5). This data is shown in Table 4.5. 
Table 4.6 exhibits patient survival rates specific to cancer deaths among late 
stage lung cancer patients.  After controlling for the patient factors affecting healthcare 
outcomes of care, the structure and process of care and the outcomes of care variables,  
patient receipt of pain medication there was only a single variable that resulted in 
statistical significance for experiencing the event of interest, death, for those prescribed 
or not prescribed medication, patient gender. Males were more likely to experience death 
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 (OR=1.31) than the females studied in the sample. The likelihood of death for patients in 
urban and rural geographies was similar.  This was also true for marital status in the 
sample. Although there were a greater number of males as well as persons who were 
single, separated or divorced this made no statistical difference.  Examining the structure 
and process of healthcare also resulted in statistical similarities for primary care and 
cancer specialist provider locations, as well as pharmacy location.  
 
Table 4.4 Descriptive characteristics of observed lung cancer patients  
 Total 
N (%) 
Opioid Receipt p 
Yes1 
N (%) 
No 
N (%)  
Sample Total 1334 (100%) 561 (42.0) 773 (58.0)  
     
Residence     
   Rural 435 (32.6) 171 (30.5) 264 (34.3) 0.33    Urban 899 (67.4) 390 (69.5) 509 (65.6) 
     
Gender     
   Male 780 (58.5)  313 (56.8) 467 (61.4) 0.29   Female 554 (41.5) 248 (44.2) 306 (39.6) 
     
Marital status2     
  Single/Separated/Divorced 531 (39.8) 227 (40.5) 304 (39.3) 0.80   Married 339 (25.4) 146 (26.0) 193 (25.0) 
  Missing 276 (20.7) 193 (34.4) 276 (37.0)  
     
Race3     
  Non-Hispanic White 636 (47.7) 288 (51.3) 348 (45.0) 0.13   Non-Hispanic Black 679 (50.1) 268 (47.7) 411 (53.2) 
1Includes single and combination prescription of opioids and analgesics 
2 191 marital status missing from patients prescribed medications. 497 marital status missing from patients not 
prescribed medications. 
319 patients removed from the Race variable to the “Other” race and ethnicity 
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 Table 4.5 Factors associated with patient cancer-related death within the 
observation period   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1Other race excluded due to the ability of the small sample size to influence the data. 2The absolute total of 
  cancer specialists is 373. 64 missing.315 primary care providers missing from the sample. 431 pharmacies 
  missing from the sample.  
 Total N 
(%) 
Cancer death 
N (%) 
Survived  
N (%) 
p 
Total 1334 
(100.0)1 
1293 (96.2) 41 (3.8) 0.11 
Patient factors     
Medications     
  Opioid received 561 (42.0) 547 (97.3) 14 (2.7) 0.63   No opioids 773 (58.0) 746 (96.5) 27 (3.5) 
Patient  Residence     
   Rural  456 (34.5) 425 (92.2) 31 (6.8) 0.51    Urban 878 (65.8) 868 (96.5) 10 (3.5) 
Gender     
   Male 780 (58.5) 761 (97.6) 19 (2.4) 0.46   Female 554 (41.5) 532 (96.1) 22 (3.9) 
Race1     
  Non-Hispanic Black 616 (46.2) 601 (97.6) 15 (2.4) 0.11   Non-Hispanic White 699 (52.5) 675 (96.6) 24 (3.4) 
Marital status     
   Single/Separated/Divorced 521 (39.1) 512 (96.4) 19 (3.6) 0.73    Married 345 (25.9) 331 (95.9) 14 (4.1) 
   Missing 458 (34.3) 450 (98.3) 8 (1.7)  
     
Structure and Process of Care     
Cancer specialist location2     
  Rural patient, rural MD 54 (1.6) 54 (100.0) 0 (0.0) 
0.81   Rural patient, urban MD 20 (1.6) 18 (90.0) 2 (10.0)   Urban patient, rural MD 19 (1.6) 18 (90.0) 1 (5.3) 
  Urban patient, urban MD 251 (20.6) 240 (95.6) 11 (4.4) 
Primary care provider location3     
  Rural patient, rural MD 388 (29.1) 379 (97.4) 9 (2.3) 
0.01   Rural patient, urban MD 46 (3.4) 45 (9.7) 1 (0.2)   Urban patient, rural MD 195 (14.6) 193 (99.0) 2 (1.0) 
  Urban patient, urban MD 690 (51.7) 671 (97.3) 29 (4.2) 
Pharmacy location4     
  Rural patient, rural pharmacy 392 (2.8) 385 (98.2) 7 (1.8) 
0.81 
  Rural patient, urban pharmacy 36 (28.9) 35 (97.2) 1 (0.8) 
  Urban patient, rural pharmacy 76 (5.8) 74 (97.4) 2 (2.6) 
  Urban patient, urban 
pharmacy 799 (60.3) 771 (96.5) 28 (3.5) 
 75 
 Table 4.6 Hazard Model for factors associated with distant stage patient death 
(N=1334) 
     1P-value for adjusted hazard ratio 2N for cancer specialist =374. P-value shown is only for the 
     unadjusted model. 
  
 Adjusted Hazard 
Ratio (95% CI) 
Unadjusted Hazard 
Ratio (95% CI) 
P1 
  
Outcomes of Care    
  Opioids prescribed (ref) 1.00 1.00 0.41   Opioids not prescribed  1.14 (0.84, 1.54) 1.09 (0.89, 1.35) 
    
Patient Factors   
0.82    Residence      Rural  1.06 (0.62, 1.84) 0.93 (0.73-1.19) 
   Urban (ref) 1.00 1.00 
    
Gender   
0.02    Male  1.31 (1.03, 1.65) 1.22 (0.98, 1.50) 
  Female (ref) 1.00 1.00 
    
Race   
0.93   Non-Hispanic Black 1.01 (0.81, 1.28) 1.01 (0.81, 1.24) 
  Non-Hispanic White (ref) 1.00 1.00 
    
Marital status   
0.79    Single/Separated/Divorced 0.96 (0.73, 1.28) 0.97 (0.75, 1.25)    Married (ref) 1.00 1.00 
   Missing 1.26 (0.84, 1.88) 1.24 (0.95, 1.63) 
    
Process/Structure    
  Physician Location   
0.36   Rural  1.26 (0.77, 2.06) 1.01 (0.80, 1.28) 
  Urban  (ref) 1.00 1.00 
    
Cancer specialist location2    
  Rural - 1.08 (0.84, 1.38) 0.56   Urban (ref) - 1.00 
    
Pharmacy location    
  Rural 0.62 (0.35, 1.09) 0.84 (0.66, 1.08) 0.09   Urban (ref) 1.00 1.00 
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 Discussion  
Study results indicate that with the exception of gender, prescribing pain 
medications does not significantly contribute to the survival rate of patients for all 
observed variables.  These findings sustain the findings of multiple international studies 
reporting that the receipt of opioid therapy does not have a significant impact on the rate 
at which patients survive.22-29 While some of the international studies did not consider 
geography or race and ethnicity in their analyses they did report the lack of influence of 
pain between patient geography and cancer survival.29-31  
Research has shown males are twice as likely to be diagnosed with lung cancer 
as well as to die of the disease in South Carolina.32 This is true in the current sample of 
patients where there is a greater representation of males who have been diagnosed with  
the disease, and the lung cancer mortality rate for males is 31% greater than the lung 
cancer mortality rate for females. The bivariate analysis demonstrated that a greater 
proportion of females survived than males. 
 
Study Limitations 
Primary limitations include: 1) the use of secondary data which restricts 
available data to only what is collected; 2) South Carolina has been declared a Health 
Professional Shortage Area for primary medical care, dental care and mental care; 3) 40% 
of South Carolina’s population inhabit rural areas; and 4) the use of a Medicaid sample 
could possibly skew demographics and results. Limiting the sample to a population of 
lower socioeconomic status persons who are transients only further complicates the 
circumstance of working with claims data.  
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 Additionally, there is limited literature depicting the United States and the US 
health care system that consistently reports the association between geographic variation 
and the prevalence and incidence of disease, treatment, and survival and lung cancer. 
Moreover, in the state of South Carolina the depiction that the literature provides is not 
dedicated to lung cancer; yet, is either broadly focused on all types of cancers, primarily 
including:, breast cancer, colon cancer or prostate cancer.  
 
Conclusion 
Lung cancer is a persistent condition in which patients require long-term care. In 
many instances, once patients are diagnosed with lung cancer the looming issue becomes 
the care or the treatment plan. This is an especially relevant circumstance for lung cancer 
patients who reside in rural areas. Normally when diagnosed, lung cancer has already 
dissipated to the regional lymph nodes or other areas of the body.33 Presented evidence 
continues to be representative of the disparities presented by distance as well as 
circumstances that prevent access to care (finances, presence of specialists, etc.).34 
Presented data does not support an explicit relationship between race and ethnicity as 
direct factors in patient survival. However, the influence of variables that commonly have 
a greater prevalence in specific racial and ethnic groups is evident from presented data. 
While there is existing policy that incentivizes clinicians who practice in remote 
areas, these benefits are only temporary. A 2011 study conducted by Merritt-Hawkins 
found that only 4% of final-year medical residents desired to practice medicine in a 
community with less than 25,000 persons.35 Policy change encouraging permanent 
residency or a greater commitment to practice medicine in remote areas is required. 
Research is needed to examine how this cultural change needs to be established in rural 
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 areas, not only considering the provider but also the possibility of a provider’s family. 
Additional policy and research needs to focus on care management plans of late stage 
cancer patients that increases patient contact (incentivizing traveling Physician Assistants 
or Nurse Practitioners, additional funding of telemedicine, etc.) with specialists. In 
addition, the education of providers on direct patient care for this specific population as 
well cultural and social influences are essential. Lastly, the increased development of 
interventional practices, like smoking cessation courses, has proven to be beneficial in the 
reduction of smoking, a linked cause of lung cancer. Increasing the availability of such 
interventions has proved behavior change and could result in the reduction of lung cancer 
diagnoses overall.  
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 CHAPTER 5 
 
CONCLUSION 
 
  
 An estimated 221,200 persons in the United States are expected to be diagnosed 
with lung cancer in 2015 (American Lung Association, 2015).  Of those Americans 
newly diagnosed and those living with the pre-existing condition, an estimated 158,040 
deaths are expected from lung cancer in 2015 alone. These deaths comprise nearly 27 
percent of overall cancer mortality (American Lung Association, 2015). Even more, the 
number of deaths resulting from lung cancer has risen approximately 3.5 percent between 
1999 and 2012, inclusive of our study years.  Patient mortality and quality of survival 
were examined in this descriptive research study with two primary goals that consider the 
influence of patient demographics and geography. The first aim of the study was to 
determine associations between patient residence (urban and rural) and the receipt of 
prescribed opioid analgesic therapy among late stage lung cancer patients. The second 
aim was to assess the association between patient residence and the patient survival rate 
of distant stage lung cancer patients, considering the receipt of opioid therapy. This 
chapter discusses the main findings of the study, strengths and limitations, policy 
implications and recommendations for future research
 83 
 5.1 Research Aim 1 
Research aim 1 addressed the urban and rural geography of patient residence 
and its association with receipt of prescribed opioid therapy among SC Medicaid lung 
cancer patients with a diagnosis.  Selected variables used to determine access to health 
care and the likelihood of patients being prescribed medications are commonly applied 
and supported in social research to contribute to both the social and health determinants 
of patients and communities.  Variables assessed in the receipt of either or both an opioid 
and analgesic were race and ethnicity (Non-Hispanic Blacks), the residential geography 
of the patient, marital status, gender, and the availability of primary care physicians and 
cancer specialists. 
These data suggest that while the mixed relationships of variables is complex, 
there are no evident trends that support the receipt of an opioid analgesics, the outcome 
measure, is associated with where patients reside as well as the race and ethnicity of 
patients.  Paper 1 of the dissertation further explored the possible relationships that have 
the potential to influence patient access to needed medications. All statistical findings 
from the regression were not statistically significant. However, bivariate analysis results 
demonstrated the statistical significance of the location of primary care providers and 
patient’s locations. These results correlate with published data stating that the disparities 
in the treatment of cancer patients can be linked to the provider from whom they receive 
treatment (Kelley, 2007).   
Rural South Carolina is affected by healthcare access issues and there are 
prominent disparities and persistent health care challenges among minority populations. 
The Centers for Disease Control and Prevention reports the prevalence of and 
contributors to chronic diseases are increased in rural regions when compared to urban 
 84 
 regions (Downey, 2013). Exacerbating risks at the person-level are communal 
characteristics that include the significant deficit of health care professionals, the lack of 
availability of specialty care, and decreased reimbursement from insurers. The disparate 
care available to rural populations is not specific to lung cancer but it can be broadly 
applied.  The availability of and access to healthcare professionals (doctors and 
pharmacists) to provide adequate treatment, the underinsuring of patients, and 
transportation are only a few factors that rural populations have to contend with to get 
needed, and deserved, healthcare. Challenges incurred by rural environments are unique.  
The existing circumstances of healthcare access for lung cancer patients in the 
rural environment have been investigated by an innumerable amount of researchers 
(Shugarman, 2008; Jong, Vale, & Armstrong, 2005); however, we were not able to 
identify any published studies to date that examined healthcare access by geography and 
its relationship to late stage lung cancer patient’s receipt of pain medication in South 
Carolina.   
 
5.2 Research Aim 2 
Research aim 2 explored the association between patient geographical residence 
and the rate of survival of distant stage lung cancer patients, considering the receipt of 
opioid therapy, either drug or both drugs. The goal of the second research aim was to 
assess patient and social factors that influenced the rate at which patients with this 
chronic condition survived. The applied bivariate analysis allowed us to study the 
availability of primary care and specialty providers in each geographic region as well as 
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 each type of providers prescribing behavior in relation to identified covariates (gender, 
marital status, and patient race/ethnicity).  
Resulting data of the bivariate analysis indicated an association between cancer 
deaths and patient race and ethnicity, as well as cancer deaths and the location of the 
primary care provider and patient residence combination variable.  The included Cox 
proportional survival analysis was unique in its examining both cancer-related deaths as 
well as non-cancer related deaths among distant stage lung cancer patients prescribed 
medication for pain. In addition to the survival analysis of each group, this was a unique 
examination of data involving provider prescribing practices among distant stage lung 
cancer Medicaid patients of South Carolina.  The only significant variable resulting from 
the survival analysis was patient gender.  Males were more likely to experience a higher 
rate of death than females in the studied sample.  
There has been no prior research found that has assessed patient access to pain 
medication in a population likely to require it in the identified geographical region (South 
Carolina), and healthcare system (Medicaid in the United States), while adjusting for a 
necessary and significant treatment variables, like the presence of cancer specialists, 
which greatly affects cancer outcomes. This current research fills this gap. 
 
Research Applications Overall, this study contributes to the current knowledge and 
literature on the disparities in healthcare access and treatment and its influence on patient 
healthcare and healthcare outcomes in the United States, but specifically creates a needed 
niche for healthcare research in South Carolina. Utilizing state-level datasets assists in 
establishing a foundation that will propel future work examining the prescribing of pain 
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 medications and influencing environmental factors and social relationships that allow or 
hinder patient access and physician prescribing behaviors in South Carolina. 
 
Study Limitations There were several limitations to this study. First, the manner in 
which availability of physicians (primary or cancer specialists) was defined did not 
capture other obstacles to patient accessibility, like transportation and distance from the 
patient, that could have prevented patient access. Secondly, the use of a secondary dataset 
restricts investigators to only what is collected or reported by hospitals, coroner’s offices, 
and providers’ offices. A third limitation of the study is the use of a Medicaid sample 
which could possibly skew demographics and results. Limiting the sample to a 
population of lower socioeconomic status persons who are commonly transient only 
further complicates the circumstance of working with claims data. A fourth and final 
limitation to the study is the declaration of South Carolina as a Health Professional 
Shortage Area for primary medical care.  This HPSA declaration is a statewide shortage 
yet will have a significantly greater impact on the rural communities of the state.  
 
Policy Implications and Future Research While there is existing policy that 
incentivizes clinicians who practice in remote areas, these benefits are only temporary. A 
2011 study conducted by Merritt-Hawkins found that only 4% of final-year medical 
residents desired to practice medicine in a community with less than 25,000 persons.  
Policy change encouraging permanent residency or a greater commitment to practice 
medicine in remote areas is required. Research is needed to examine methods to 
strategically building the infrastructure of rural areas, not only considering the provider 
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 but also the possibility of a provider’s family. Building such an infrastructure will require 
an investment.  Most importantly additional policy and research needs to focus on care 
management plans of late stage cancer patients that increases patient contact (creating 
and incentivizing clinical specialty tracks for Physician Assistants or Nurse Practitioners 
who will be willing to relocate or travel, additional funding of telemedicine, etc.) with 
specialists. 
Additionally, demands for changes in local and national policy that monitor the 
availability of pain medications in rural communities are necessary, simply to ensure 
availability of adequate amounts of medications to meet the needs of the population. 
Increasing accessibility to highly addictive pain medications for certain populations raises 
concerns of patient abuse or the diversion of medications.  One manner to combat this is 
the appropriate and mandated use of prescription monitoring programs.  Not only should 
the use of these prescription monitoring programs be mandated, but also requiring the 
utilization of systems that have the ability to communicate with one another. The 
overprescribing opioids is a public health issue that puts an economic strain on financial 
and health resources. In addition, it is necessary to increase provider’s awareness of the 
direct care needs for this specific population as well as cultural and social influences 
through education. Lastly, the increased development of interventional practices, like 
smoking cessation courses, have proven to be beneficial in the reduction of smoking, a 
cause of lung cancer. Increasing the availability of such interventions has resulted in 
significant behavior change and could result in the reduction of lung cancer diagnoses 
overall.  
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